Waters (WAT) 10-K risk factor changes: FY2021 vs FY2020
The 2021-12-31 10-K against the 2020-12-31 one, compared heading by heading and sentence by sentence.
Item 1A30 rewritten54 added37 removed170 unchanged
All filing items1,046 rewritten548 added589 removed1,808 unchanged
Sentence counts leave out repeated page headers and footers. 4 of those lines differ and are listed apart under each item.
Summary
counted, not written
- Item 1A headings could not be compared: only 0 carried over between the two years, which usually means one filing was read wrongly, so none is reported as new or removed.
- Sentence by sentence, 548 added, 589 removed, 1,046 rewritten and 1,808 unchanged across 21 items that differ.
- Not counted above: 4 repeated page header or footer lines also differ. They are listed apart under each item.
- New this year: Item 1B. Unresolved Staff Comments; Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.
- Not in this year's filing: Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Sentences by item
23 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2021; struck-through words were in FY2020. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. Risk Factors
30 rewritten, 54 added, 37 removed, 170 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Such measures have had and are expected to continue to have adverse impacts on the [removed: U.S.] [added: United States] and foreign economies of uncertain severity and [removed: duration] [added: duration,] and have had and may continue to have a negative impact on the Company’s operations, including [removed: the Company’s] [added: Company] sales, supply chain and cash flow.
pandemic [removed: also] has [removed: the potential] [added: and may continue] to [removed: significantly] [added: have a significant] impact [added: on] our supply chain if our manufacturing facilities or those of third parties to whom we outsource certain manufacturing processes, the distribution centers where our inventory is managed or the operations of our logistics and other service providers are disrupted, temporarily closed or experience worker shortages.
We [added: have and] may [removed: also see] [added: continue to have] disruptions or delays in shipments of certain materials or components of our products.
[removed: As company employees work from home] and access the Company’s [removed: system] [added: systems] remotely, the Company may be subject to heightened security risks, including the risks of cyber-attacks.
[removed: Additionally,] [added: Furthermore, the Company’s business could be adversely affected] if any of the Company’s key management employees are unable to perform their duties for a period of time, including as [removed: the] [added: a] result of [removed: illness, the Company’s business, results of operations and financial condition could be adversely affected.][added: illness.]
[removed: Ultimately, the][added: The]
Approximately [added: 72% and] 71% of the Company’s net sales in [removed: both 2020] [added: 2021] and [removed: 2019] [added: 2020, respectively,] were outside of the United States and were primarily denominated in foreign currencies.
As a result, a significant portion of the Company’s sales and operations are subject to certain risks, including adverse developments in the political, regulatory and economic environment, in particular, uncertainty regarding possible changes to foreign and domestic trade policy; the effect of the U.K.’s exit from the European Union as well as the financial difficulties and debt burden experienced by a number of European countries; the instability and potential impact of war or terrorism; the instability and possible dissolution of the Euro as a single currency; sudden movements in a country’s foreign exchange rates due to a change in a country’s sovereign risk profile or foreign exchange regulatory practices; tariffs and other trade barriers; the impact of [removed: public] [added: global] health [added: pandemics and] epidemics, such as [removed: the coronavirus currently impacting China and elsewhere; difficulties in staffing and managing foreign operations; and associated adverse operational, contractual and tax consequences.]
Approximately [removed: 59%] [added: 60%] and [removed: 57%] [added: 59%] of the Company’s net sales in [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] respectively, were to worldwide pharmaceutical and biotechnology companies, which may be periodically subject to unfavorable market conditions and consolidations.
The Company is in the process of developing new products with recently acquired [added: technologies.]
The future development of these new products will require a significant amount of spending over [removed: the next few years before significant, robust sales will be realized.]
Certain components or modules of the Company’s LC and MS instruments are manufactured by outside contractors, including the manufacturing of LC instrument systems and related components by contract [added: manufacturing firms in Singapore.]
[removed: The] [added: Prior to April 1, 2021, the] Company [removed: has] [added: had] a tax exemption in Singapore on certain types of [removed: income through March 2021,] [added: income,] based upon the achievement and continued satisfaction of certain operational and financial milestones, which the Company met as of December 31, 2020 and [removed: expects to maintain] [added: maintained] through March 2021.
[removed: Currently, the] [added: The] Company [removed: has] [added: had] determined that it [removed: is] [added: was] more likely than not to realize the tax exemption in Singapore and, accordingly, [removed: has] [added: did] not [removed: recognized] [added: recognize] any reserves for unrecognized tax benefits on its balance sheet related to this tax exemption.
[removed: In the event that] [added: If] any of the milestone targets were not met, the Company would not [removed: be] [added: have been] entitled to the tax exemption on income earned in Singapore dating back to the start date of the agreement (April 1, 2016), and all the tax benefits previously recognized would be reversed, resulting in the recognition of income tax expense equal to the statutory tax of 17% on income earned during that period.
[removed: In addition, the] [added: The] Company [removed: has] [added: entered into] a new Development and Expansion Incentive in Singapore that provides a concessionary income tax rate of 5% on certain types of income for the period April 1, 2021 through March 31, 2026.
The market for employees in our industry is extremely competitive, and competitors for talent, particularly engineering talent, increasingly attempt to hire, and to varying degrees have [removed: been successful in hiring, our employees.]
None of the Company’s key management employees, with the exception of the [removed: President and] Chief Executive [added: Officer and Chief Financial] Officer, have an employment contract with the Company and there can be no assurance that such individuals will remain with the Company.
[removed: Additionally, if,] [added: If,] for any reason, other key personnel do not continue to be active in management, the Company’s results of operations or financial condition could be adversely affected.
[removed: Additionally, we must maintain and periodically upgrade our information and web-based] systems, which has caused and will in the future cause temporary interruptions to our technology infrastructure.
[removed: In addition, at times, the Company faces attempts by third] parties to defeat its security measures or exploit vulnerabilities in its systems.
While we continue to enhance our controls, we cannot be certain that we will be able to prevent future significant deficiencies or material [removed: weaknesses.]
In [removed: 2019,] [added: 2020,] the Company was not able to determine with certainty the country of origin of some of the conflict minerals in its manufactured products.
The Company is in the process of evaluating its [removed: 2020] [added: 2021] supply chain, and the Company plans to file its [removed: 2020] [added: 2021] Form SD with the SEC in May [removed: 2021.][added: 2022.]
In the event that any future climate change legislation would require that stricter standards be imposed by domestic or international environmental regulatory authorities with respect to the use and/or levels of possible [added: emissions from such chemicals and/or other substances, the Company may be required to make certain changes and adaptations to its manufacturing processes.]
[removed: The Company sponsors various retirement plans, both inside and outside the U.S.] Any changes in regulations made by governments in countries in which the Company sponsors retirement plans could adversely impact the Company’s cash flows or results of operations.
For example, changes in long-term interest rates affect the discount rate that is used to measure the Company’s retirement plan [removed: obligations and related expense.]
The Company had [removed: $1.4] [added: $1.5] billion in debt and [removed: $443] [added: $569] million in cash, cash equivalents and investments as of December 31, [removed: 2020.][added: 2021.]
As of December 31, [removed: 2020,] [added: 2021,] the Company also had the ability to borrow an additional [removed: $1.4] [added: $1.6] billion from its existing, committed credit facility.
All but a small portion of the Company’s debt was in the U.S. There is a substantial cash requirement in the [removed: U.S.] [added: United States] to fund operations and capital expenditures, service debt interest obligations, finance potential [removed: U.S.] [added: United States] acquisitions and continue authorized stock repurchase programs.
The adverse effects of the continuing
pandemic and an indeterminate recovery period has negatively affected the Company’s business and operations, and may continue to negatively impact the Company’s business and operations, the nature and extent of such impact is highly uncertain.
The impact of the global
pandemic over the last two years has resulted in a widespread public health crisis.
pandemic has caused significant volatility and continued spread throughout the United States and globally, which has disrupted and may continue to disrupt the Company’s business.
In response, governments of most countries, including the United States, as well as private businesses, have implemented numerous measures attempting to contain and mitigate the effects of
COVID-19.
The current logistic and supply chain issues being experienced throughout the world have made it more difficult for us to manage our operations and as such we cannot provide any assurances that any further disruptions in the logistics and supply chains will not have a material impact on our future financial results and cashflows.
In addition, in the event of a sustained downturn in customer demand or other economic conditions due to the
pandemic could result in material charges related to bad debt or inventory write-offs, restructuring charges, or impairments of long-lived assets, including both tangible and intangible assets.
Furthermore, such a sustained downturn in financial markets and asset values could adversely affect the Company’s cost of capital, liquidity and access to capital markets.
pandemic has caused the Company to take measures to modify its business practices.
We have invested in maintaining safe work environments for our employees by, among other things, adding work from home flexibility, adjusting attendance policies to encourage those who are sick to stay at home, increasing cleaning protocols across all work locations, initiating regular communications regarding the impacts of the
pandemic, establishing new physical distancing and safety procedures for employees, modifying workplaces as appropriate and implementing protocols to address actual and suspected
cases and potential exposure.
Further, the Company has modified policies regarding employee travel and physical participation in meetings, events and conferences.
The Company may take further actions as may be required by government authorities or that the Company determines are in the best interests of, among others, its employees, customers, distributors and suppliers.
The Company’s change in business practices may result in the Company experiencing lower workforce efficiency and productivity.
In addition, as Company employees work from home
Although we are in
re-opening
processes for our corporate and other facilities, such processes may face future closure requirements.
There is no certainty that the Company measures will be sufficient to mitigate the risks posed by
COVID-19,
and the Company’s ability to perform critical functions could be adversely impacted.
The degree to which
ultimately affects the Company’s business, financial results and operations will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, including the effect of the emergence of variants of the virus, its severity, the actions to contain the virus or treat its impact, the availability, distribution, acceptance and efficacy of a vaccine, and how quickly and to what extent normal economic and operating conditions can resume.
COVID-19;
difficulties in staffing and managing foreign operations; and associated adverse operational, contractual and tax consequences.
the next few years before significant, robust sales will be realized.
been successful in hiring, our employees.
For example, in December 2021, a vulnerability named “Log4Shell” was reported for the widely used Java logging library, Apache Log4j 2.
We have reviewed the use of this library within our software product portfolio and in our IT environment and have taken steps to mitigate the vulnerability.
To date, cybersecurity incidents have not resulted in a material adverse impact to our business or operations, but there can be no guarantee we will not experience such an impact.
Additionally, we must maintain and periodically upgrade our information and
web-based
In addition, at times, the Company faces attempts by third
weaknesses.
Environmental, social and corporate governance (“ESG”) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation.
There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters.
The Company’s business has been and may continue to be negatively affected by outbreaks of disease, such as epidemics or pandemics, including the ongoing
pandemic.
Outbreaks of disease, such as epidemics or pandemics, have and could continue to negatively affect the Company’s business.
Both the Company’s domestic and international operations have been and continue to be adversely affected by the ongoing global
pandemic and the resulting volatility and uncertainty it has caused in the U.S. and international markets.
Since being declared a pandemic in March 2020 by the World Health,
has continued to spread throughout the U.S. and globally.
pandemic has caused significant volatility and uncertainty in U.S. and international markets, which has disrupted and is expected to continue to disrupt the Company’s business and could result in a prolonged economic downturn.
Many countries, including the U.S., have implemented measures such as quarantine,
shelter-in-place,
curfew and similar isolation measures, including government orders and other restrictions on the conduct of business operations.
Certain jurisdictions have experienced increased numbers of
infections following the
re-openings
of their economies and easing of restrictions, which, in some cases, has required closings of certain business activity and the imposition of other restrictions in response.
It is unclear whether the increases in the number of infections will continue and amplify or whether any
so-called
“second waves” of
infections will be experienced in the United States or elsewhere and, if so, what the impact of that would be on human health and safety, the economy and our business.
Although the FDA has approved certain therapies and two vaccines for emergency use and distribution, the initial rollout of vaccine distribution has encountered significant delays and there remains uncertainties about the amount of vaccine available for distribution, the logistics of implementing a national vaccine program and the overall efficacy of the vaccines once widely administered, especially as new strains of
have been discovered, and the level of resistance these new strains have to the existing vaccines remains unknown.
Additionally, the widespread pandemic has caused and is expected to continue to cause significant disruption of global financial markets, which may reduce the Company’s ability to access capital.
As a result of the ongoing
pandemic, the Company has transitioned the majority of its workforce to a temporary remote working model, which may result in the Company experiencing lower workforce efficiency and productivity, which in turn may adversely affect the Company’s business, results of operations and financial condition.
The Company cannot reasonably estimate the length or severity of the
pandemic or the related response, or the extent to which the disruption may continue to impact the Company’s business, financial position, results of operations and cash flows.
pandemic could have a material adverse impact on the Company’s business, financial positions, results of operations and cash flows.
technologies.
manufacturing firms in Singapore.
On December 31, 2020, our Senior Vice President and Chief Financial Officer departed from the Company and the Company appointed an interim Chief Financial Officer, effective January 1, 2021.
We are currently conducting a search for a new Chief Financial Officer.
Competition for experienced talent is intense and our process to search for a successor may be time-consuming and divert the board of directors’ and managements’ attention away from our business.
This search and any eventual transition to a permanent Chief Financial Officer may be disruptive to our operations.
Any delay or failure in identifying, attracting or retaining a permanent Chief Financial Officer, and successfully managing this leadership transition could have an adverse effect on our results of operations or financial condition.
emissions from such chemicals and/or other substances, the Company may be required to make certain changes and adaptations to its manufacturing processes.
| Item 1B: Unresolved | Staff Comments |
None.
An excerpt. Shown here: all 30 rewritten, 40 of 54 added and all 37 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2021 filing and the FY2020 filing.
Page headers and footers: 2 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
COVID-19
Item 7. Management
180 rewritten, 125 added, 138 removed, 260 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Business [removed: and Financial] Overview
The Company’s products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic and [removed: governmental] [added: government] customers.
Both the Company’s domestic and international operations have been and continue to be [removed: adversely] affected by the ongoing global [removed: pandemic of a novel strain of coronavirus]
[removed: (“COVID-19”)][added: pre-COVID-19]
[added: pandemic] that has led to volatility and uncertainty in the U.S. and international markets.
[removed: pandemic] [added: pandemic, including the effect of the emergence of variants of the virus,] or the related response, or the extent to which the disruption may materially impact the Company’s business, consolidated financial position, consolidated results of operations or consolidated cash flows in the future.
[removed: In 2020, the][added: The]
pandemic [removed: did] [added: has] not materially [removed: impact] [added: impacted] the Company’s manufacturing facilities or those of the third parties to whom it outsources certain manufacturing processes, the distribution centers where its inventory is managed, or the operations of its logistics and other service providers.
[removed: The Company has engaged a medical advisor to guide its policy deployment,] [added: pandemic,] and [removed: the Company] continues to take proactive measures to guard the health of its global employee [removed: base,] [added: base] and the safety of all customer interactions.
The Company has implemented rigorous protocols to promote a safe work environment in all of its locations [added: that are operational] around the world and continues to closely monitor and update its multi-phase process [removed: that was developed during the year to ensure] for the safe return of employees to [removed: its] [added: their] physical workplaces as social distancing, governmental [removed: requirements] [added: requirements, including capacity limitations,] and other protocols allow.
The vast majority of the markets the Company serves, most notably the pharmaceutical, biomedical research, [added: materials sciences,] food/environmental and clinical markets, have continued to operate at various levels, and the Company is working closely with these customers to facilitate their seamless operation.
pandemic continues to be fluid with uncertainties and risks [removed: remaining] across the global economy.
[removed: The] [added: During 2020, the] Company took a proactive approach [removed: to] managing through this unpredictability and implemented a series of cost reduction [removed: actions that include] [added: actions, which included temporary] salary reductions, furloughs and reductions in
The Company’s operating results are as follows for the years ended December 31, [removed: 2020, 2019] [added: 2021, 2020] and [removed: 2018] [added: 2019] (dollars in thousands, except per share data):
| | | [removed: 2020] [added: 2021] | | | | [removed: 2019] [added: 2020] | | | | [removed: 2018] [added: 2019] | | | | [removed: 2020] [added: 2021] vs. [removed: 2019] [added: 2020] | | | | [removed: 2019] [added: 2020] vs. [removed: 2018] [added: 2019] | | |
| Product sales | | $ | [removed: 1,497,333] [added: 1,822,070] | | | $ | [removed: 1,567,189] [added: 1,497,333] | | | $ | [removed: 1,604,993] [added: 1,567,189] | | | | [removed: (4] [added: 22] | [removed: %)] [added: %] | | | [removed: (2] [added: (4] | %) |
| Service sales | | | [removed: 868,032] [added: 963,804] | | | | [removed: 839,407] [added: 868,032] | | | | [removed: 814,936] [added: 839,407] | | | | [removed: 3] [added: 11] | % | | | 3 | % |
| Total net sales | | | [removed: 2,365,365] [added: 2,785,874] | | | | [removed: 2,406,596] [added: 2,365,365] | | | | [removed: 2,419,929] [added: 2,406,596] | | | | [removed: (2] [added: 18] | [removed: %)] [added: %] | | | [removed: (1] [added: (2] | %) |
| Cost of sales | | | [removed: 1,006,689] [added: 1,156,533] | | | | [removed: 1,010,700] [added: 1,006,689] | | | | [removed: 992,564] [added: 1,010,700] | | | | [removed: —] [added: 15] | [added: %] | | | [removed: 2] [added: —] | % |
| Selling and administrative expenses | | | [removed: 553,698] [added: 626,968] | | | | [removed: 534,791] [added: 553,698] | | | | [removed: 536,902] [added: 534,791] | | | | [removed: 4] [added: 13] | % | | | [removed: —] [added: 4] | [added: %] |
| Research and development expenses | | | [removed: 140,777] [added: 168,358] | | | | [removed: 142,955] [added: 140,777] | | | | [removed: 143,403] [added: 142,955] | | | | [removed: (2] [added: 20] | [removed: %)] [added: %] | | | [removed: —] [added: (2] | [added: %)] |
| Purchased intangibles amortization | | | [removed: 10,587] [added: 7,143] | | | | [removed: 9,693] [added: 10,587] | | | | [removed: 7,712] [added: 9,693] | | | | [removed: 9] [added: (33] | [removed: %] [added: %)] | | | [removed: 26] [added: 9] | % |
| Asset impairments | | | [removed: 6,945 | | | |] — | | | | [removed: — | | | | *] [added: 6,945] | [removed: *] | | | — | |
| Litigation provision [removed: (settlement)] | | | [removed: 1,180] [added: 5,165] | | | | [removed: —] [added: 1,180] | | | | [removed: (426] [added: —] | [removed: )] | | | [removed: *] [added: 338] | [removed: *] [added: %] | | | * | * |
| Operating income | | | [removed: 645,489] [added: 821,707] | | | | [removed: 708,457] [added: 645,489] | | | | [removed: 739,774] [added: 708,457] | | | | [removed: (9] [added: 27] | [removed: %)] [added: %] | | | [removed: (4] [added: (9] | %) |
| Operating income as a % of sales | | | [removed: 27.3] [added: 29.5] | % | | | [removed: 29.4] [added: 27.3] | % | | | [removed: 30.6] [added: 29.4] | % | | | | | | | | |
| Other [removed: expense] [added: income (expense), net] | | | [removed: (1,775] [added: 17,203] | [removed: )] | | | [removed: (3,586] [added: (1,775] | ) | | | [removed: (47,794] [added: (3,586] | ) | | | [removed: (51] [added: *] | [removed: %)] [added: *] | | | [removed: *] [added: 51] | [removed: *] [added: %] |
| Interest expense, net | | | [removed: (32,800] [added: (32,717] | ) | | | [removed: (26,632] [added: (32,800] | ) | | | [removed: (9,834] [added: (26,632] | ) | | | [removed: 23] [added: —] | % | | | [removed: *] [added: (23] | [removed: *] [added: %)] |
| Income before income taxes | | | [removed: 610,914] [added: 806,193] | | | | [removed: 678,239] [added: 610,914] | | | | [removed: 682,146] [added: 678,239] | | | | [removed: (10] [added: 32] | [removed: %)] [added: %] | | | [removed: (1] [added: (10] | %) |
| Provision for income taxes | | | [removed: 89,343] [added: 113,350] | | | | [removed: 86,041] [added: 89,343] | | | | [removed: 88,352] [added: 86,041] | | | | [removed: 4] [added: 27] | % | | | [removed: (3] [added: 4] | [removed: %)] [added: %] |
| Net income | | $ | [removed: 521,571] [added: 692,843] | | | $ | [removed: 592,198] [added: 521,571] | | | $ | [removed: 593,794] [added: 592,198] | | | | [removed: (12] [added: 33] | [removed: %)] [added: %] | | | [removed: —] [added: (12] | [added: %)] |
| Net income per diluted common share | | $ | [removed: 8.36] [added: 11.17] | | | $ | [removed: 8.69] [added: 8.36] | | | $ | [removed: 7.65] [added: 8.69] | | | | [removed: (4] [added: 34] | [removed: %)] [added: %] | | | [removed: 14] [added: (4] | [removed: %] [added: %)] |
The Company’s net sales [removed: decreased] [added: increased] approximately [removed: 2%] [added: 18%] in [removed: 2020] [added: 2021] as compared to [removed: 2019,] [added: 2020,] and decreased [removed: 1%] [added: 2%] in [removed: 2019] [added: 2020] as compared to [removed: 2018.][added: 2019.]
[removed: COVID-19 pandemic][added: Pandemic]
Foreign currency translation increased sales by [added: 2% and] less than 1% [removed: and decreased sales by 2%] in [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] respectively.
The Company’s [added: recent] acquisitions [removed: of Andrew Alliance (as defined below) and ISS (as defined below)] did not have material impacts on sales [removed: growth in 2020.][added: growth.]
Instrument system sales [added: increased 23% in 2021 and] decreased 8% [removed: and 4%] in [removed: 2020 and 2019, respectively.][added: 2020.]
In [removed: 2020, the decrease in] [added: 2020 Waters] instrument system sales [removed: was attributable] [added: (LC and MS technology-based) decreased 8%, primarily attributed] to the weaker demand for our products [added: and services] by our customers due to [removed: interruption of business activities and] the [added: disruption and] uncertainty caused [removed: by]
Foreign currency translation [removed: increased] [added: had minimal impact on] instrument system sales [removed: by 1%] in [removed: 2020] [added: 2021] and [removed: decreased] [added: increased] sales by 1% in [removed: 2019.][added: 2020.]
Recurring revenues (combined sales of precision chemistry consumables and services) increased [removed: 4%] [added: 13%] and [removed: 3%] [added: 4%] in [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] respectively, as a result of a larger installed base of customers and higher billing demand for service sales.
Management
s Discussion and Analysis of Financial Condition and
However, the current logistic and supply chain issues being experienced throughout the world have made it more difficult for us to manage our operations and as such we cannot provide any assurances that any further disruptions in the logistics and supply chains will not have a material impact on our future financial results and cashflows.
The Company has taken decisive and appropriate actions throughout the
The
These cost reductions were completed by the end of 2020 and reduced the Company’s spending by approximately $100 million in 2020.
The majority of these cost saving actions were reinstated at the beginning of 2021, which negatively impacted the Company’s cashflows in 2021 and also attributed to the increase in expenses as a result of the normalization of these costs.
Financial Overview
The increase in sales in 2021 can be attributed to the strong sales performance across most major geographies, end markets, and product categories due to customer demand continuing to return to
pre-pandemic
normal operations.
In 2021, the increase in instrument system sales was attributable to customer demand continuing to increase to
pandemic levels as customer laboratories and manufacturing facilities continued to return to normal operations.
This strength in 2021 was broad-based, particularly in LC,
and TA instrument system sales.
Geographically, the sales growth in 2021 was broad-based across the world, and was due to customer demand continuing to increase to
pre-pandemic
levels as customer laboratories and manufacturing facilities continued to return to normal operations.
In 2021, the strong sales performance was broad-based across all regions, with sales increasing 20% in Asia, 16% in the Americas, and 17% in Europe.
The pharmaceutical sales growth was driven by strong double-digit growth in all major regions, including 45% in China, 26% in India, 17% in the Americas and 15% in Europe as strong customer demand continued to recover to
pre-pandemic
levels.
Foreign currency translation added 4% to Europe sales growth in 2021.
This increase in sales to industrial customers was driven by the TA business as TA’s sales grew 26% in 2021 as compared to a decline of 8% in 2020.
Operating income was $822 million in 2021, an increase of 27% as compared to 2020.
This increase was primarily a result of the increase in sales volumes caused by our customers resuming laboratory and manufacturing operations throughout the world and the favorable impact of foreign currency translation.
In addition, in the second half of 2021, the Company’s operating income was negatively impacted by higher freight costs and higher costs associated with certain electronic components.
The operating income decline was partially mitigated by a series of cost reduction actions, equaling $100 million, implemented by the Company in 2020.
Operating income as a percentage of sales was 29.5%, 27.3% and 29.4% in 2021, 2020 and 2019, respectively.
The 2020 operating income percentage decreased as a result of the decrease in sales volume due to the
In addition, the 2020 operating margin benefited by the $100 million of cost reduction actions.
The 2021 operating income margin was negatively impacted by the cost actions as these costs had been reinstated by the beginning of 2021.
Included in the 2021, 2020 and 2019 net cash flow from operations is $38 million,
The remainder of the liability is required to be paid in annual installments of $72 million, $96 million and $121 million in 2023, 2024 and 2025, respectively.
The Company has incurred costs of $200 million on this facility through the end of 2021, and anticipates spending approximately $50 million to complete this new state-of-the-art facility in 2022.
On September 17, 2021, the Company entered into an amended and restated credit agreement (the “2021 Credit Agreement”), which amended the Company’s existing credit agreement entered into in 2017 (the “2017 Credit Agreement”).
As of December 31, 2021, the 2021 Credit Facility had a total of $210 million outstanding.
As of December 31, 2020, the revolving credit facility and the term loan governed by the 2017 Credit Agreement had a total of $100 million and $300 million, respectively, outstanding.
The 2021 Credit Facility matures on September 17, 2026 and requires no scheduled prepayments before that date.
In March 2021, the Company issued senior unsecured notes with an aggregate principal amount of $500 million.
At every stage of the pandemic, the Company has taken decisive and appropriate actions, including a mandatory remote work policy for all employees with the exception of those in manufacturing, distribution, and certain laboratory environments, as well as restrictions on
travel and visitors into its facilities.
Over the last several years, the Company has executed on a digital workplace strategy focused on providing modern connectivity and
collaboration tools to its employees.
The Company’s strategic technology investments have enabled it to swiftly meet remote working needs as the
situation has escalated and evolved.
From a customer-facing perspective, the Company is leveraging digital demand generation activities, including virtual demos across all regions in which it operates, remote instrument installations, virtual sales seminars, online product training, and a rapid acceleration in
one-on-one
communications over emails, phone and video conferencing.
While the Company initially anticipated that the
pandemic would have the biggest impact on the Company’s financial results in the second quarter of 2020, and future quarters would improve as countries lifted their business restrictions, the new outbreaks of
in the U.S. and elsewhere throughout the world have demonstrated that the
These cost reductions were completed by the end of 2020; however, the Company’s plan will be adjusted accordingly depending on the pace of the recovery and any further lockdowns.
The decline in sales in 2020 can be attributed to the lower customer demand due to interruption in business activities caused by the uncertainties from the
across the world.
The negative impact of
on our business was more pronounced in the first half of 2020 as the Company’s sales declined 12% as compared to the prior year.
In the second half of 2020, our customers began to resume laboratory and manufacturing operations and it resulted in the Company’s second half sales growing 7% as compared to the prior year.
the COVID-19 pandemic.
As
customer demand started to return to normal levels, instrument system sales increased 3% in the second half of 2020 as compared to the prior year period, after having declined 22% in the first half of 2020 compared to the prior year period.
In 2019, the decrease in instrument system sales was primarily driven by weaker demand for our products by our customers due to uncertainty caused by macroeconomic conditions and governmental policy changes.
the COVID-19 pandemic.
As our customers began to resume laboratory and manufacturing operations, recurring revenues increased 10% in the second half of 2020 as compared to the prior year period, after having declined 3% in the first half of 2020 compared to the prior year period.
In 2020, the sales decline in Asia was primarily driven by the 8% decrease in sales in China due to lower demand caused by the
pandemic.
The decline in the Company’s sales in 2019 was a result of increased sales in the U.S., Canada, Japan and the rest of Asia being offset by a decrease in sales in other geographies on weaker demand for our products due to uncertainty caused by macroeconomic conditions, primarily from Brexit as well as Latin America, and governmental policy changes in China.
Sales in the Americas decreased 4% and 1% in 2020 and 2019, respectively, with foreign currency translation having minimal impact on sales in 2020 and negatively impacting sales by 1% in 2019.
Sales to pharmaceutical customers increased 2% and were flat in 2020 and 2019, respectively, with foreign currency translation positively impacting sales by 1% in 2020 and negatively impacting sales by 2% in 2019.
Similarly, TA sales declined 8% and 4% in 2020 and 2019, respectively.
Combined sales to academic and governmental customers decreased 16% in 2020 and increased 2% in 2019, with foreign currency translation having minimal impact on sales in 2020 and decreasing sales by 1% in 2019.
The decline in sales to academic and governmental customers in 2020 was due to the lower demand for our products and services as the academic and governmental institutions adjusted their spending during the year to mitigate the effects of
The most significant decline in academic and governmental sales in 2020 occurred in China where sales declined 31% due to government-mandated spending reductions.
Operating income decreased 4% in 2019 as compared to 2018.
This decrease can be attributed to lower sales volume, the effect of foreign currency translation and $10 million of severance-related costs in connection with a reduction in workforce that occurred in early 2019, offset by lower variable incentive compensation costs.
In 2018, the Company settled a pension plan obligation and incurred a $46 million expense which reduced the net income per diluted share by $0.39.
The increase in operating cash flow in 2019 was primarily a result of payments made in 2018 that did not recur, including $103 million of income tax payments made in the U.S. relating to the Company’s estimated 2017 transition tax liability and 2018 estimated tax payments, a $15 million litigation settlement payment and $11 million of contributions to certain defined benefit pension plans.
The final 60% of the total liability is required to be paid over a three-year period beginning in 2023.
In January of 2020, the Company acquired all of the outstanding stock of Andrew Alliance, S.A. and its two operating subsidiaries, Andrew Alliance USA, Inc. and Andrew Alliance France, SASU (collectively “Andrew Alliance”), for $80 million, net of cash acquired.
The Company had an equity investment in Andrew Alliance that was valued at $4 million and included as part of the total consideration.
An excerpt. Shown here: 40 of 180 rewritten, 40 of 125 added and 40 of 138 removed. The counts are complete. For every sentence, read Item 7. Management in the FY2021 filing and the FY2020 filing.
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
23 rewritten, 1 added, 1 removed, 38 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
As of December 31, [removed: 2020,] [added: 2021,] the Company [removed: has entered into] [added: had] three-year interest rate cross-currency swap derivative agreements with a notional value of [removed: $560] [added: $230] million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.
Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency [added: translation adjustment in other comprehensive income and remain in accumulated comprehensive income in stockholders’ equity (deficit) until the sale or substantial liquidation of the foreign operation.]
| | | December 31, [removed: 2020] [added: 2021] | | | | | | | | December 31, [removed: 2019] [added: 2020] | | | | | | |
| Other current assets | | $ | [removed: 66,690] [added: 55,309] | | | $ | [removed: 836] [added: 504] | | | $ | [removed: 119,576] [added: 66,690] | | | $ | [removed: 16] [added: 836] | |
| Other current liabilities | | $ | [removed: 20,000] [added: 9,000] | | | $ | [removed: 185] [added: 195] | | | $ | [removed: 29,495] [added: 20,000] | | | $ | [removed: 1,028] [added: 185] | |
| Other [removed: (liabilities) assets] [added: liabilities] | | $ | [removed: 560,000] [added: 230,000] | | | $ | [removed: (44,996] [added: 5,363] | [removed: )] | | $ | 560,000 | | | $ | [removed: 4,485] [added: 44,996] | |
| Accumulated other comprehensive loss [removed: (income)] | | | | | | $ | [removed: 44,996] [added: 15,944] | | | | | | | $ | [removed: (4,485] [added: 44,996] | [removed: )] |
The following is a summary of the activity included in the [added: consolidated] statements of [added: operations and statements of] comprehensive income related to the foreign currency exchange contracts [added: and interest rate cross-currency swap agreements] (in thousands):
| | | [removed: 2020] [added: 2021] | | | | [removed: 2019] [added: 2020] | | | | [removed: 2018] [added: 2019] | | | | |
| Realized [removed: gains] (losses) [added: gains] on closed contracts | | Cost of sales | | $ | [removed: 1,444] [added: (1,973] | [added: )] | | $ | [removed: (3,552] [added: 1,444] | [removed: )] | | $ | [removed: (6,684] [added: (3,552] | ) |
| Unrealized [removed: gains] (losses) [added: gains] on open contracts | | Cost of sales | | | [removed: 1,663] [added: (343] | [added: )] | | | [removed: (1,292] [added: 1,663] | [removed: )] | | | [removed: (105] [added: (1,292] | ) |
| Cumulative net pre-tax [removed: gains] (losses) [added: gains] | | Cost of sales | | $ | [removed: 3,107] [added: (2,316] | [added: )] | | $ | [removed: (4,844] [added: 3,107] | [removed: )] | | $ | [removed: (6,789] [added: (4,844] | ) |
| Interest earned | | Interest income | | $ | [removed: 15,296] [added: 11,084] | | | $ | [removed: 11,709] [added: 15,296] | | | $ | [removed: 2,713] [added: 11,709] | |
| Unrealized [removed: (losses)] gains [added: (losses)] on open contracts | | [removed: Stockholders’ equity (deficit)] [added: Accumulated other comprehensive loss] | | $ | [removed: (44,996] [added: 29,052] | [removed: )] | | $ | [removed: 4,485] [added: (44,996] | [added: )] | | $ | [removed: 1,093] [added: 4,485] | |
exchange rates (a strengthening of the U.S. dollar), the fair market value of the foreign currency exchange contracts outstanding as of December 31, [removed: 2020] [added: 2021] would decrease
earnings by approximately [removed: $9] [added: $5] million.
exchange rates (a strengthening of the U.S. dollar), the fair market value of the interest rate cross-currency swap agreements outstanding as of December 31, [removed: 2020] [added: 2021] would increase by approximately [removed: $56] [added: $23] million and would be recorded to foreign currency translation in other comprehensive income within stockholders’ equity (deficit).
As of December 31, [removed: 2020,] [added: 2021,] the carrying value of the Company’s cash and cash equivalents approximated fair value.
As of December 31, [removed: 2020,] [added: 2021,] the Company estimates that a hypothetical adverse change of 100 basis points across all maturities would not have a material effect on the fair market value of its portfolio.
As of December 31, [removed: 2020] [added: 2021] and [removed: 2019, $364] [added: 2020, $440] million out of [removed: $443] [added: $569] million and [removed: $249] [added: $364] million out of [removed: $337] [added: $443] million, respectively, of the Company’s total cash, cash equivalents and investments were held by foreign subsidiaries.
In addition, [removed: $254] [added: $298] million out of [removed: $443] [added: $569] million and [removed: $176] [added: $254] million out of [removed: $337] [added: $443] million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at December 31, [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] respectively.
As of December 31, [removed: 2020,] [added: 2021,] the Company had no holdings in auction rate securities or commercial paper issued by structured investment vehicles.
exchange rates (a strengthening of the U.S. dollar), the fair market value of the Company’s cash, cash equivalents and investments held in currencies other than the U.S. dollar as of December 31, [removed: 2020] [added: 2021] would decrease by approximately [removed: $25] [added: $30] million, of which the majority would be recorded to foreign currency translation in other comprehensive income within stockholders’ [removed: equity (deficit).][added: equity.]
Quantitative and Qualitative Disclosures About Market Risk
translation adjustment in other comprehensive income and remain in accumulated comprehensive income in stockholders’ equity (deficit) until the sale or substantial liquidation of the foreign operation.
Item 1. Business
43 rewritten, 42 added, 53 removed, 375 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
[removed: Waters Corporation (the “Company,”] [added: ,”] “we,” “our,” or “us”) is a specialty measurement company that operates with a fundamental underlying purpose to advance the science that enables our customers to enhance human health and well-being.
[added: Waters] has pioneered analytical workflow solutions involving liquid chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years.
In addition, the Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA [added: Instruments]
[added: (“TA”)] product line.
Bio System, a versatile, [removed: iron-free,]
[removed: bio-inert,][added: Bio]
[removed: quaternary] liquid chromatograph specifically engineered to improve bioseparation analytical methods.
The Company also introduced [removed: the ACQUITY][added: a new peptide]
[added: The Company also introduced the ACQUITY] UPLC PLUS series in 2018, consisting of [removed: the]
[added: the] H-Class
PLUS, [added: H-Class PLUS]
[removed: PLUS Bio] and [added: I-Class PLUS]
[removed: PLUS] systems, which incorporate foundational enhancements into the legacy systems.
[removed: high-performance surface] [added: High Performance Surface (“HPS”)] technology.
[added: (“Q-Tof”)] instruments, such as the Company’s SYNAPT
Based upon [added: 2021] reports from independent marketing research firms and publicly-disclosed sales figures from competitors, the Company believes that it is one of the world’s largest manufacturers and distributors of LC and
The Company has been a developer and supplier of software-based products that interface with [added: both] the Company’s [removed: instruments, as well as] [added: and] other suppliers’ instruments.
The Company’s newest software [removed: technology, UNIFI][added: technology is the waters_connect]
The Company’s principal competitors in the service market include PerkinElmer, Inc., Agilent Technologies, [removed: Inc.,] [added: Inc. and] Thermo Fisher Scientific Inc. [added: These competitors can provide certain services on Waters instruments to varying degrees] and [removed: General Electric Company.][added: always present competitive risk.]
The servicing and support of instruments, software and accessories is an important source of revenue and represented over 35% of sales for Waters in [removed: 2020.][added: 2021.]
In 2020, TA introduced the new Discovery X3 Differential Scanning [removed: Calorimeter,] [added: Calorimeter (“X3 DSC”),] Discovery Hybrid Rheometers and TAM IV Micro XL isothermal microcalorimeter.
[removed: These products support] [added: The new line of Discovery Hybrid Rheometers provides increased sensitivity and versatility of rheometry measurements, supporting] the development of next-generation, high-performance materials by improving the productivity and efficiency of materials science research.
Similar to Waters, the servicing and support of TA’s instruments is an important source of revenue and represented more than [removed: 25%] [added: 20%] of sales for TA in [removed: 2020.][added: 2021.]
During [removed: 2020, 59%] [added: 2021, 60%] of the Company’s net sales were to pharmaceutical accounts, 30% to other industrial accounts and [removed: 11%] [added: 10%] to academic institutions and governmental agencies.
During fiscal years [removed: 2020, 2019] [added: 2021, 2020] and [removed: 2018,] [added: 2019,] no single customer accounted for more than 2% of the Company’s net sales.
Across these product technologies, using respective specialized sales and service workforces, the Company serves its customer base with [removed: 83] [added: 82] sales offices throughout the world as of December 31, [removed: 2020] [added: 2021] and approximately [removed: 4,000,] [added: 4,300,] 4,000 and [removed: 3,900] [added: 4,000] field representatives in [removed: 2020, 2019] [added: 2021, 2020] and [removed: 2018,] [added: 2019,] respectively.
In February 2018, the Company’s Board of Directors approved expanding its Taunton [removed: location and anticipates spending an estimated $215 million to build and equip this new][added: location.]
The Company has incurred [removed: $151 million of] costs [added: of $200 million] on this facility through the end of [removed: 2020.][added: 2021, and anticipates spending approximately $50 million to complete this new state-of-the-art facility in 2022.]
[added: The instruments, components or] modules are then returned to the Company’s facilities, where its engineers perform final assembly, calibrations to customer specifications and quality control procedures.
TA’s thermal analysis, rheometry and calorimetry products are manufactured and distributed at the Company’s New Castle, Delaware, [removed: Wakefield, Massachusetts,] Eden Prairie, Minnesota, Lindon, Utah and Huellhorst, Germany facilities.
The Company’s New Castle facility is certified to ISO 9001:2015 and ISO 17025:2005 standards and the Eden Prairie facility is certified to both ISO 9001:2015 and ISO/IEC 17025:2017 [removed: standards.][added: standards, and the Lindon facility is certified to ISO 9001:2015.]
In [removed: 2019,] [added: 2020,] the Company was not able to determine with certainty the country of origin of some of the conflict minerals in its manufactured products.
The Company is in the process of evaluating its [removed: 2020] [added: 2021] supply chain, and the Company plans to file its [removed: 2020] [added: 2021] Form SD with the SEC in May [removed: 2021.][added: 2022.]
The Company’s research and development expenditures for [removed: 2020, 2019] [added: 2021, 2020] and [removed: 2018] [added: 2019] were [removed: $141] [added: $168] million, [removed: $143] [added: $141] million and $143 million, respectively.
At December 31, [removed: 2020, 2019] [added: 2021, 2020] and [removed: 2018,] [added: 2019,] there were [removed: 1,112, 1,089] [added: 1,150, 1,112] and [removed: 1,011] [added: 1,089] employees, respectively, involved in the Company’s research and development efforts.
The Company employed approximately [removed: 7,400, 7,500] [added: 7,800, 7,400] and [removed: 7,200] [added: 7,500] employees at December 31, [removed: 2020,] [added: 2021,] December 31, [removed: 2019] [added: 2020] and [removed: 2018,] [added: 2019,] respectively, with approximately [removed: 38%] [added: 39%] of the Company’s employees located in the United States.
| | • | | Modifying workspaces as appropriate; [removed: and] |
| | • | | Implementing protocols to address actual and suspected COVID-19 cases and potential [removed: exposure.] [added: exposure; and] |
In the markets served by Waters, the Company’s principal competitors include: Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc. In the markets served by TA, the Company’s principal competitors include: PerkinElmer, Inc., [removed: Mettler-Toledo International Inc.,] NETZSCH-Geraetebau GmbH, Thermo Fisher Scientific Inc., Malvern PANalytical Ltd., a subsidiary of Spectris plc, [added: Mettler-Toledo International Inc.] and Anton-Paar GmbH.
[removed: The Company is subject to foreign and U.S. federal, state and local laws, regulations and ordinances that (i) govern activities or operations that may have adverse environmental effects, such as discharges to air and] water as well as handling and disposal practices for solid and hazardous wastes, and (ii) impose liability for the costs of cleaning up and certain damages resulting from sites of past spills, disposals or other releases of hazardous substances.
Waters Corporation (the “Company,” “Waters
iron-free, bio-inert, quaternary
In 2021, the Company introduced the new ACQUITY PREMIER LC solution and the Arc Premier System both featuring Waters’ MaxPeak
MaxPeak
HPS technology, which was first introduced with the
Company’s introduction of ACQUITY
PREMIER Columns in 2020, is a surface technology that forms a barrier between the sample and the metal surfaces of both the system and column, eliminating the need for system passivation, mitigating the loss of metal-sensitive analytes and yielding higher quality data in less time and effort.
HPS technology.
In 2021, the Company introduced the Waters SELECT SERIES
MRT, a high-resolution mass spectrometer that combines Multi-Reflecting
Time-of-Flight
(“MRT”) technology with enhanced desorption electrospray ionization and new matrix-assisted laser desorption ionization imaging sources.
The platform will serve as the basis for Waters’ next generation Tof instruments with applications in pharmaceutical, biomedical, natural products, and materials research.
Also in 2021, the Company released the ACQUITY RDa
Detector featuring SmartMS
, the company’s newest Tof MS designed to improve the ease and reliability of small molecule analysis for pharmaceutical, academic, food, and forensic applications.
multi-attribute method workflow for the BioAccord
system in 2021, which is an end to end workflow for analyzing monoclonal antibodies and other protein and peptide based drugs.
LC-MS
platform.
In 2019, the Company introduced the first of a series of applications on this platform supporting the BioAccord system and the Xevo G2 XS mass spectrometers.
These applications support biopharmaceutical workflows, simplifying the collection of often complex LCMS data for use in biopharmaceutical development and into QC where it is used to assure the quality of existing medicines and new drug formulations.
The platform design of waters_connect has enabled rapid delivery of several major updates including new biopharma application workflows designed in close collaboration with biopharmaceutical innovators to solve specific challenges they face with existing solutions.
The platform also provides the foundation for the connected lab of the future where data is no longer siloed but can be securely shared among a community of connected scientists.
Waters_connect joins the existing suite of informatics products – Empower
In 2020, Waters announced the availability of Waters Empower BC LAC/ETM with SecureSync, a newly enhanced solution to preserve the ability for laboratories to work locally when organizations with distributed laboratory environments experience an enterprise interruption.
The X3 DSC accelerates productivity in customers’ laboratories by enabling three samples to be measured in a single experiment, compared to the single-sample series operation of the other available DSC offerings in the market.
This particularly addresses a need in high-throughput laboratories in industries such as composites, electronics and polymer manufacturing.
The TAM IV Micro XL isothermal calorimeter supports the development of new battery chemistries by measuring self-discharge and unwanted reactions that reduce battery life and efficiency.
In 2021, TA introduced the TMA 450RH and the Discovery SA.
The TMA 450RH provides measurements of dimensional compatibility of materials under controlled temperature and humidity that are important for the development of new electronic devices.
The Discovery SA is used in pharmaceutical development to assess the impact of moisture in drug product processing and storage on crystalline structure, which is related to drug product efficacy.
In 2021, TA introduced the TRIOS AutoPilot software for its thermal analyzer product line.
This software helps laboratory staff using TA’s thermal analyzers create routine and streamlined standard operating procedures improving the speed and productivity of thermal analysis measurements.
We believe that part of fostering an inclusive and increasingly racially and ethnically diverse workforce requires understanding the makeup of our current employees.
As of December 31, 2021, our workforce is:
| | • | | 32% female, with women occupying 30% of company leadership roles (defined as Senior Director or above) compared with 18% in 2016, a 12% increase; and |
| | • | | 19% racially and/or ethnically diverse, with 9% of our workforce identifying as Asian, 3% as Black or African American, 6% identifying as Hispanic/Latinx and 1% identifying as two or more races. |
Recruitment
| | • | | Continuing to modify and evolve our COVID-19 response plan as governments issue new recommendations and guidelines. |
Waters
TM
TM
TM
TM
TM
H-Class
I-Class
TM
TM
TM
In 2018, the Company introduced the BioResolve
TM
RP mAb Polyphenyl columns, which improve the consistency and reliability of the overly complex separations of monoclonal antibodies and antibody-drug conjugates.
In 2018, the Company introduced the VICAM
BPATest
, which provides a sensitive, precise determination of Bisphenol A in as little as ten minutes.
VICAM also introduced a user-friendly lateral flow zearalenone strip test, the
Zearala-V
AQUA
in 2018.
(“Q-Tof”)
In 2018, the Company introduced the DART QDa
system with LiveID
, a direct-from-sample analytical system that verifies sample authenticity or adulteration, specifically for food applications.
The Company also introduced the Xevo
TQ-GC
mass spectrometer in 2018, which allows laboratories to meet and exceed low
part-per-billion
limits of detection when quantifying pesticide residues and other contaminants in food using
GC-MS/MS
methods set forth by worldwide regulatory agencies/authorities.
In addition, the Company introduced the RenataDX
screening system, a flow-injection tandem mass spectrometry system for rapid high-throughput analysis of extracted dried blood spots and other human biological matrices.
, is a scientific information system that is the culmination of a multi-year effort to substantially bring all of Waters’ preexisting, distinct software systems under one operating system.
UNIFI joins Waters’ suite of
informatics products – Empower
UNIFI is the industry’s first comprehensive software that seamlessly integrates UPLC chromatography, mass spectrometry and informatics data workflows.
In 2018, the Company announced new analysis capabilities across a variety of molecules by integrating UNIFI acquired data from the Company’s
Vion
An excerpt. Shown here: 40 of 43 rewritten, 40 of 42 added and 40 of 53 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2021 filing and the FY2020 filing.
Cover and table of contents
37 rewritten, 13 added, 9 removed, 48 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
For the fiscal year ended December 31, [removed: 2020][added: 2021]
[removed: |] Securities registered pursuant to Section 12(b) of the Act: [removed: |]
| Common [removed: Stock,] [added: Stock ,] par value $0.01 per share | | WAT | | New York Stock [removed: Exchange,] [added: Exchange ,] Inc. |
Yes [removed: ☑ No ☐]
Yes ☐ No [removed: ☑]
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 [removed: days.][added: days]
Yes [removed: ☑]
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such [removed: files).][added: files]
Yes [removed: ☑ No ☐]
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit [removed: report.]
Yes ☐ [removed: No ☑]
of the registrant as of [added: July 3, 202]
Indicate the number of shares outstanding of the registrant’s common stock as of February [added: 18, 2022: 60,515,620]
Portions of the registrant’s definitive proxy statement that will be filed for the [removed: 2021] [added: 2022] Annual Meeting of Stockholders are incorporated by reference in Part III.
| | | | | [removed: PART I] [added: [PART I](#tx208871_1)] | | | | |
| | 1A. | | | [Risk [removed: Factors](#tx32803_2)] [added: Factors](#tx208871_3)] | | | [removed: 15] [added: 16] | |
| | 1B. | | | [Unresolved Staff [removed: Comments](#tx32803_3)] [added: Comments](#tx208871_4)] | | | [removed: 24] [added: 25] | |
| | 3. | | | [Legal [removed: Proceedings](#tx32803_5)] [added: Proceedings](#tx208871_6)] | | | [removed: 25] [added: 27] | |
| | 4. | | | [Mine Safety [removed: Disclosures](#tx32803_6)] [added: Disclosures](#tx208871_7)] | | | [removed: 25] [added: 27] | |
| | | | | [Information About [removed: Out] [added: Our] Executive [removed: Officers](#tx32803_7)] [added: Officers](#tx208871_8)] | | | [removed: 25] [added: 102] | |
| | | | | [removed: PART II] [added: [PART II](#tx208871_9)] | | | | |
| | 5. | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#tx32803_8)] [added: Securities](#tx208871_10)] | | | [removed: 27] [added: 28] | |
| | 7. | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#tx32803_10)] [added: Operations](#tx208871_12)] | | | 31 | |
| | 7A. | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#tx32803_11)] [added: Risk](#tx208871_13)] | | | [removed: 49] [added: 48] | |
| | 8. | | | [Financial Statements and Supplementary [removed: Data](#tx32803_12)] [added: Data](#tx208871_14)] | | | [removed: 52] [added: 51] | |
| | 9. | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#tx32803_13)] [added: Disclosure](#tx208871_16)] | | | [removed: 104] [added: 102] | |
| | 9A. | | | [Controls and [removed: Procedures](#tx32803_14)] [added: Procedures](#tx208871_17)] | | | [removed: 104] [added: 102] | |
| | 9B. | | | [Other [removed: Information](#tx32803_15)] [added: Information](#tx208871_18)] | | | [removed: 104] [added: 102] | |
| | | | | [removed: PART III] [added: [PART III](#tx208871_20)] | | | | |
| | 10. | | | [Directors, Executive Officers and Corporate [removed: Governance](#tx32803_16)] [added: Governance](#tx208871_21)] | | | [removed: 105] [added: 102] | |
| | 11. | | | [Executive [removed: Compensation](#tx32803_17)] [added: Compensation](#tx208871_22)] | | | [removed: 105] [added: 104] | |
| | 12. | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#tx32803_18)] [added: Matters](#tx208871_23)] | | | [removed: 105] [added: 104] | |
| | 13. | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#tx32803_19)] [added: Independence](#tx208871_24)] | | | [removed: 106] [added: 105] | |
| | 14. | | | [Principal Accountant Fees and [removed: Services](#tx32803_20)] [added: Services](#tx208871_25)] | | | [removed: 106] [added: 105] | |
| | | | | [removed: PART IV] [added: [PART IV](#tx208871_26)] | | | | |
| | 15. | | | [Exhibits and Financial Statement [removed: Schedules](#tx32803_21)] [added: Schedules](#tx208871_27)] | | | [removed: 107] [added: 106] | |
| | 16. | | | [Form 10-K [removed: Summary](#tx32803_22)] [added: Summary](#tx208871_28)] | | | [removed: 111] [added: 110] | |
☑ No ☐
☑ No ☐
).
☑ No ☐
report.
No
: $21,855,696,546.
| | 1. | | | [Business](#tx208871_2) | | | 3 | |
| | 2. | | | [Properties](#tx208871_5) | | | 26 | |
| | 6. | | | [Reserved](#tx208871_11) | | | 31 | |
| | | | | [Report of Independent Registered Public Accounting Firm (PCAOB ID 238)](#tx208871_15) | | | 52 | |
| | 9C. | | | [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#tx208871_19) | | | 102 | |
| | | | | [Signatures](#tx208871_29) | | | 111 | |
##### [Table of Contents](#toc)
No ☐
6/27/2020: $
10,820,434,917.
, 2021: 62,185,690
| | 1. | | | [Business](#tx32803_1) | | | 3 | |
| | 2. | | | [Properties](#tx32803_4) | | | 24 | |
| | 6. | | | [Selected Financial Data](#tx32803_9) | | | 30 | |
| | | | | [Signatures](#tx32803_23) | | | 112 | |
Item 1B. Unresolved Staff Comments
0 rewritten, 2 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2021 item · filed February 24, 2022
Unresolved Staff Comments
None.
Item 2. Properties
30 rewritten, 6 added, 3 removed, 9 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Waters Corporation operates [removed: 20] [added: 19] United States facilities and [removed: 71] [added: 69] international facilities, including field offices.
Primary Facility Locations [added: (1)]
| Location | | Function [removed: (1)] [added: (2)] | | Owned/Leased | [added: | |]
| Golden, CO | | M, R, S, D, A | | [added: |] Leased | [added: |]
| New Castle, DE | | M, R, S, D, A | | [added: |] Owned | [added: |]
| Franklin, MA | | D | | [added: |] Leased | [added: |]
| Milford, MA | | M, R, S, A | | [added: |] Owned | [added: |]
| Taunton, MA | | M, R | | [added: |] Owned | [added: |]
| Cambridge, MA | | R, S | | [added: |] Leased | [added: |]
| Eden Prairie, MN | | M, R, S, D, A | | [added: |] Leased | [added: |]
| Nixa, MO | | M, S, D, A | | [added: |] Leased | [added: |]
| Lindon, UT | | M, R, S, D, A | | [added: |] Leased | [added: |]
| Solihull, England | | [removed: M,A] [added: M, A] | | [added: |] Owned | [added: |]
| Wilmslow, England | | M, R, S, D, A | | [added: |] Owned | [added: |]
| St. Quentin, France | | S, A | | [added: |] Leased | [added: |]
| Huellhorst, Germany | | M, R, S, D, A | | [added: |] Owned | [added: |]
| Wexford, Ireland | | M, R, D, A | | [added: |] Owned | [added: |]
| Bangalore, India | | M, S, D, A | | [added: |] Owned | [added: |]
| Etten-Leur, Netherlands | | S, D, A | | [added: |] Owned | [added: |]
| Brasov, Romania | | R, A | | [added: |] Leased | [added: |]
| Singapore | | R, S, D, A | | [added: |] Leased | [added: |]
| [removed: (1)] [added: (2)] | M = Manufacturing; R = Research; S = Sales and Service; D = Distribution; A = Administration |
The Company operates and maintains [removed: 10] [added: 9] field offices in the United States and [removed: 59] [added: 56] field offices abroad in addition to sales offices in the primary facilities listed above.
Field Office Locations [removed: (2)][added: (3)]
| Columbia, MD | | Canada | | Italy | | [removed: Spain] [added: Puerto Rico] |
| Morrisville, NC | | Czech Republic | | Japan | | [removed: Sweden] [added: Spain] |
| Parsippany, NJ | | Denmark | | Korea | | [removed: Switzerland] [added: Sweden] |
| Plymouth Meeting, PA | | Finland | | Malaysia | | [removed: Taiwan] [added: Switzerland] |
| Bellaire, TX | | France | | Mexico | | [removed: United Arab Emirates] [added: Taiwan] |
| [removed: (2)] [added: (3)] | The Company operates more than one field office within certain states and foreign countries. |
| Beijing, China | | S, A | | | Leased | |
| Shanghai, China | | S, A | | | Leased | |
| Hong Kong | | S, A | | | Leased | |
| (1) | The Company operates more than one primary facility within certain states and foreign countries. |
| | | Germany | | Netherlands | | United Arab Emirates |
| | | | | | | United Kingdom |
| Newcastle, England | | R, S, D, A | | Leased |
| Budapest, Hungary | | R | | Leased |
| Salt Lake City, UT | | Germany | | Netherlands | | United Kingdom |
Item 4. Mine Safety Disclosures
0 rewritten, 31 added, 48 removed, 3 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
| Item 5: Market | for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |
The Company’s common stock is registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is listed on the New York Stock Exchange under the symbol “WAT”.
As of February 19, 2022, the Company had 75 common stockholders of record.
The Company has not declared or paid any dividends on its common stock in its past three fiscal years and does not intend to pay cash dividends in the foreseeable future.
Any future determination to pay cash dividends will be made at the discretion of the Board of Directors and will depend on restrictions and other factors the Board of Directors may deem relevant.
The Company has not made any sales of unregistered equity securities in the years ended December 31, 2021, 2020 or 2019.
Securities Authorized for Issuance under Equity Compensation Plans
Equity compensation plan information is incorporated by reference from Part III, Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, of this document and should be considered an integral part of this Item 5.
Stock Price Performance Graph
The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into such filing.
The following graph compares the cumulative total return on $100 invested as of December 31, 2016 (the last day of public trading of the Company’s common stock in fiscal year 2016) through December 31, 2021 (the last day of public trading of the common stock in fiscal year 2021) in the Company’s common stock, the NYSE Market Index, the SIC Code 3826 Index and the S&P 500 Index.
The return of the indices is calculated assuming reinvestment of dividends during the period presented.
The Company has not paid any dividends since its IPO.
The stock price performance shown on the graph below is not necessarily indicative of future price performance.
COMPARISON OF CUMULATIVE TOTAL RETURN SINCE DECEMBER 31, 2016
AMONG WATERS CORPORATION, NYSE MARKET INDEX, SIC CODE 3826 INDEX – LABORATORY ANALYTICAL INSTRUMENTS AND S&P 500 INDEX

| | | 2016 | | | | 2017 | | | | 2018 | | | | 2019 | | | | 2020 | | | | 2021 | | |
| WATERS CORPORATION | | | 100.00 | | | | 143.75 | | | | 140.38 | | | | 173.86 | | | | 184.11 | | | | 277.25 | |
| NYSE MARKET INDEX | | | 100.00 | | | | 118.73 | | | | 108.10 | | | | 135.68 | | | | 145.16 | | | | 175.18 | |
| SIC CODE INDEX | | | 100.00 | | | | 121.83 | | | | 116.49 | | | | 153.17 | | | | 181.35 | | | | 233.41 | |
| S&P 500 INDEX | | | 100.00 | | | | 139.02 | | | | 142.44 | | | | 200.67 | | | | 275.70 | | | | 372.23 | |
Purchases of Equity Securities by the Issuer
The following table provides information about purchases by the Company during the three months ended December 31, 2021 of equity securities registered by the Company under the Exchange Act (in thousands, except per share data):
| Period | | Total Number of Shares Purchased (1) | | | | Average Price Paid per Share | | | | Total Number of Shares Purchased as Part of Publicly Announced Programs | | | | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Programs (2) | | |
| October 3, 2021 to October 30, 2021 | | | 145 | | | $ | 351.92 | | | | 145 | | | $ | 989,582 | |
| October 31, 2021 to November 27, 2021 | | | 141 | | | $ | 348.42 | | | | 141 | | | $ | 940,385 | |
| November 28, 2021 to December 31, 2021 | | | 162 | | | $ | 346.16 | | | | 162 | | | $ | 884,561 | |
| Total | | | 448 | | | $ | 348.74 | | | | 448 | | | $ | 884,561 | |
| (1) | The Company repurchased less than one thousand shares of common stock at a cost of less than $1 million related to the vesting of restricted stock during the three months ended December 31, 2021. |
| (2) | In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a two-year period. This program replaced the remaining amounts available under the pre-existing authorization. In December 2020, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2023. The size and timing of these purchases, if any, will depend on our stock price and market and business conditions, as well as other factors. |
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Officers of the Company are elected annually by the Board of Directors and hold office at the discretion of the Board of Directors.
The following persons serve as executive officers of the Company:
Dr. Udit Batra, 50, was appointed a Director of the Company as well as President and CEO on September 1, 2020.
He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020.
Prior to that, Dr. Batra served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany’s Consumer Health business.
Dr. Batra oversaw the company’s Bioethics Advisory Panel and had Board responsibility for the global Information Technology function.
Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts.
Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and
non-profit
sectors.
Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer.
Keeley Aleman, 44, was appointed Senior Vice President, General Counsel and Secretary in October of 2019.
Ms. Aleman joined Waters Corporation in 2006 as the Assistant General Counsel and held various legal roles focusing on business transactions, commercial strategies, international development, compliance, corporate governance and organizational matters.
Prior to joining Waters Corporation she held corporate associate positions at Goodwin Procter, LLP, and Testa, Hurwitz & Thibeault, LLP.
Robert G.
Carson, 47, was appointed Senior Vice President, Corporate Development in February 2018.
Prior to joining Waters Corporation, he held several positions during his 16 years at Medtronic plc, including Vice President and General Manager, Pacemaker Business from January 2017 to January 2018.
In addition, Mr. Carson spent nearly 12 years in Medtronic’s spinal implants and biologics business, serving as Vice President and General Manager from July 2016 to January 2017, Vice President of Global Marketing & Strategy from April 2015 to July 2016 and Vice President & Therapy Segment Leader from October 2012 to April 2015.
Mr. Carson began his career with Banc of America Securities.
Dr. Michael C.
Harrington, 60, was appointed Senior Vice President, Global Markets in February 2016.
Dr. Harrington joined Waters Corporation in 1987 and has held several senior positions with Waters Corporation, including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations.
Prior to joining Waters Corporation, Dr. Harrington held senior sales positions at Celsis, Inc.
Belinda Hyde, 50, was appointed Senior Vice President, Global Human Resources of Waters Corporation in January 2021.
She is responsible for all aspects of the Global Human Resources function including talent management, total rewards, HR business partners, HR operations and technology, employee engagement and diversity and inclusion.
Prior to joining Waters, Belinda served as the Chief Human Resources Officer for SPX FLOW, from July 2015 to December 2020, and Schnitzer Steel.
She has also held leadership roles in business and cultural transformation, executive development, talent management, compensation, benefits, training, internal communications and business partner support at companies such as Caltex Petroleum, Dell Technologies, Invitrogen and Celanese Corporation.
Belinda earned a Bachelor of Arts in psychology from the University of Texas, as well as both a master’s degree and doctorate in industrial and organizational psychology from the University of Houston.
Ian S.
King, 64, was appointed Senior Vice President, Global Products in July 2017.
Mr. King joined Waters in 1982 and previously served as Senior Vice President, Instrument Technology; Vice President, Separations Technologies; and Vice President and General Manager of Consumable Division, as well as a variety of scientific and management positions in Waters Corporation’s international subsidiaries.
Prior to joining Waters Corporation, Mr. King worked at Edinburgh University as a research scientist.
Jonathan M.
Pratt, 51, was appointed Senior Vice President and President, TA Instruments in August 2019.
Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life Sciences from January 2017 to April 2019.
Additionally, he held senior positions at Pall Corporation from 2001 to 2017, where he was Vice President and General Manager from October 2015 to December 2016 following Pall Corporation’s acquisition by Danaher Corporation and, prior to that, President of its Food & Beverage, Laboratory and ForteBio businesses from April 2011 to October 2015.
In August 2020, Mr. Pratt was appointed to the Board of SPX FLOW, Inc. (NYSE:FLOW) as an independent director and a member of the Audit, Compensation, and Nominating & Governance Committees.
Michael F.
Silveira, 54, was elected by the Board of Directors of the Company to serve as the interim Chief Financial Officer, effective January 1, 2021.
An excerpt. Shown here: all 0 rewritten, all 31 added and 40 of 48 removed. The counts are complete. For every sentence, read Item 4. Mine Safety Disclosures in the FY2021 filing and the FY2020 filing.
Item 6. Reserved
0 rewritten, 1 added, 36 removed, 0 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Reserved
The following table sets forth selected historical consolidated financial and operating data for the periods indicated.
The statement of operations and balance sheet data is derived from financial statements for the years 2020, 2019, 2018, 2017 and 2016.
The Company’s financial statements as of December 31, 2020 and 2019, and for each of the three years in the period ended December 31, 2020 are included in Part II, Item 8, Financial Statements and Supplementary Data, of this Form
10-K.
| In thousands, except per share and employees data | | 2020 | | | | 2019 | | | | 2018 | | | | 2017 | | | | 2016 | | |
| STATEMENT OF OPERATIONS DATA: | | | | | | | | | | | | | | | | | | | | |
| Net sales | | $ | 2,365,365 | | | $ | 2,406,596 | | | $ | 2,419,929 | | | $ | 2,309,078 | | | $ | 2,167,423 | |
| Income from operations before income taxes | | $ | 610,914 | | | $ | 678,239 | | | $ | 682,146 | | | $ | 641,097 | | | $ | 600,114 | |
| Net income* | | $ | 521,571 | | | $ | 592,198 | | | $ | 593,794 | | | $ | 20,311 | | | $ | 521,503 | |
| Net income per basic common share* | | $ | 8.40 | | | $ | 8.76 | | | $ | 7.71 | | | $ | 0.25 | | | $ | 6.46 | |
| Weighted-average number of basic common shares | | | 62,094 | | | | 67,627 | | | | 76,992 | | | | 79,793 | | | | 80,786 | |
| Net income per diluted common share* | | $ | 8.36 | | | $ | 8.69 | | | $ | 7.65 | | | $ | 0.25 | | | $ | 6.41 | |
| Weighted-average number of diluted common shares and equivalents | | | 62,414 | | | | 68,166 | | | | 77,618 | | | | 80,604 | | | | 81,417 | |
| BALANCE SHEET AND OTHER DATA: | | | | | | | | | | | | | | | | | | | | |
| Cash, cash equivalents and investments | | $ | 443,146 | | | $ | 337,144 | | | $ | 1,735,224 | | | $ | 3,393,701 | | | $ | 2,813,032 | |
| Working capital, including current maturities of debt | | $ | 596,050 | | | $ | 721,157 | | | $ | 2,214,232 | | | $ | 3,663,977 | | | $ | 3,115,124 | |
| Total assets | | $ | 2,839,920 | | | $ | 2,557,055 | | | $ | 3,727,426 | | | $ | 5,324,354 | | | $ | 4,662,059 | |
| Long-term debt | | $ | 1,206,515 | | | $ | 1,580,797 | | | $ | 1,148,172 | | | $ | 1,897,501 | | | $ | 1,701,966 | |
| Stockholders’ equity (deficit)* | | $ | 232,144 | | | $ | (216,281 | ) | | $ | 1,567,258 | | | $ | 2,233,788 | | | $ | 2,301,949 | |
| Employees | | | 7,412 | | | | 7,467 | | | | 7,246 | | | | 7,020 | | | | 6,899 | |
| * | The provision for income taxes for 2017 includes a $550 million estimate for the impact of the enactment of the 2017 Tax Act, which was signed into law on December 22, 2017. The $550 million income tax provision reduced net income per share by $6.82. The $550 million income tax provision primarily consists of an estimated transition tax, as well as estimated income tax provisions for state and withholding taxes and a provision associated with the remeasurement of the Company’s deferred tax assets and liabilities from 35% to the new U.S. corporate income tax rate of 21%. |
The Company adopted new accounting guidance related to stock-based compensation in 2017.
The new accounting guidance requires the excess tax benefits or deficiencies related to stock-based compensation to be reflected in the consolidated statements of operations as a component of the provision for income taxes, whereas they were previously recognized in equity.
This aspect of the new accounting guidance was required to be adopted on a prospective basis for the statement of operations and retroactive restatement was not permitted.
In 2020, 2019 and 2018, the Company recognized an excess tax benefit, which decreased income tax expense by $7 million, $9 million and $9 million, respectively, and added $0.11, $0.14 and $0.11, respectively, to net income per diluted share.
In addition, in December 2018, the Company settled a pension plan obligation by making
lump-sum
cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan’s obligations.
As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million
non-cash
charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity.
The $46 million
pre-tax
charge reduced net income per diluted share by $0.39.
| | In January 2019, the company adopted new accounting guidance related to the accounting for leases. The new guidance requires lessees to present the assets and liabilities that arise from leases on their balance sheets. The standard required using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. As a result, the Company recorded a $93 million right-of-use asset as of December 31, 2019. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows and stockholders’ equity (deficit). |
| * | In 2018, the Company adopted new accounting guidance which eliminates the deferral of tax effects on intra-entity transfers other than inventory and requires an entity to recognize the income tax consequences when the transfer occurs. The Company adopted this standard as of January 1, 2018 with a $4 million charge to beginning retained earnings in the consolidated balance sheet. |
Item 8. Financial Statements and Supplementary Data
609 rewritten, 211 added, 215 removed, 795 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, [removed: 2020.][added: 2021.]
The effectiveness of our internal control over financial reporting as of December 31, [removed: 2020] [added: 2021] has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.
We have audited the accompanying consolidated balance sheets of Waters Corporation and its subsidiaries (the “Company”) as of December 31, [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] and the related consolidated statements of operations, of comprehensive income, of stockholders’ equity (deficit) and of cash flows for each of the three years in the period ended December 31, [removed: 2020,] [added: 2021,] including the related notes (collectively referred to as the “consolidated financial statements”).
We also have audited the Company’s internal control over financial reporting as of December 31, [removed: 2020,] [added: 2021,] based on criteria established in
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2020] [added: 2021] in conformity with accounting principles generally accepted in the United States of America.
Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2020,] [added: 2021,] based on criteria established in
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in [removed: accordance with generally accepted accounting principles.]
As described in Notes 2 and 8 to the consolidated financial statements, the Company’s consolidated goodwill balance was [removed: $444] [added: $438] million as of December 31, [removed: 2020.][added: 2021.]
These procedures also included, among others, (i) testing management’s process for developing the fair value estimates; (ii) evaluating the appropriateness of the discounted cash flow models; [added: (iii) testing the completeness and accuracy of underlying data used in the models; and (iv) evaluating the significant assumptions used by management related to the estimated growth rates.]
[removed: Evaluating management’s] assumptions related to estimated revenue growth rates involved evaluating whether the growth rates used by management were reasonable considering the current and past performance of the reporting units and whether those growth rates were consistent with evidence obtained in other areas of the audit.
[removed: | February 24,] [added: ,] 2021 [removed: |]
| | | [added: 2021 | | | |] 2020 | | | | 2019 | | |
| Cash and cash equivalents [added: at beginning of period] | | [removed: $] | 436,695 | | | [removed: $] | 335,715 | | [added: | | 796,280 | |]
| Investments | | | [removed: 6,451] [added: 68,051] | | | | [removed: 1,429] [added: 6,451] | |
| Accounts receivable, net | | | [removed: 573,316] [added: 612,648] | | | | [removed: 587,734] [added: 573,316] | |
| Inventories | | | [removed: 304,281] [added: 356,095] | | | | [removed: 320,551] [added: 304,281] | |
| Other current assets | | | [removed: 80,290] [added: 90,914] | | | | [removed: 67,062] [added: 80,290] | |
| Total current assets | | | [removed: 1,401,033] [added: 1,628,942] | | | | [removed: 1,312,491] [added: 1,401,033] | |
| Property, plant and equipment, net | | | [removed: 494,003] [added: 547,913] | | | | [removed: 417,342] [added: 494,003] | |
| Intangible assets, net | | | [removed: 258,645] [added: 242,401] | | | | [removed: 240,203] [added: 258,645] | |
| Goodwill | | | [removed: 444,362] [added: 437,865] | | | | [removed: 356,128] [added: 444,362] | |
| Operating lease assets | | | [removed: 93,252] [added: 84,734] | | | | [removed: 93,358] [added: 93,252] | |
| Other assets | | | [removed: 148,625] [added: 153,077] | | | | [removed: 137,533] [added: 148,625] | |
| Total assets | | $ | [removed: 2,839,920] [added: 3,094,932] | | | $ | [removed: 2,557,055] [added: 2,839,920] | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY [removed: (DEFICIT)] | | | | | | | | |
| Notes payable and debt | | $ | [removed: 150,000] [added: —] | | | $ | [removed: 100,366] [added: 150,000] | |
| Accounts payable | | | [removed: 72,212] [added: 96,799] | | | | [removed: 49,001] [added: 72,212] | |
| Accrued employee compensation | | | [removed: 72,166] [added: 101,192] | | | | [removed: 43,467] [added: 72,166] | |
| Deferred revenue and customer advances | | | [removed: 198,240] [added: 227,561] | | | | [removed: 176,360] [added: 198,240] | |
| Current operating lease liabilities | | | [removed: 27,764] [added: 27,906] | | | | [removed: 27,125] [added: 27,764] | |
| Accrued income taxes | | | [removed: 76,558] [added: 61,278] | | | | [removed: 45,967] [added: 76,558] | |
| Accrued warranty | | | [removed: 10,950] [added: 10,718] | | | | [removed: 11,964] [added: 10,950] | |
| Other current liabilities | | | [removed: 197,093] [added: 155,054] | | | | [removed: 137,084] [added: 197,093] | |
| Total current liabilities | | | [removed: 804,983] [added: 680,508] | | | | [removed: 591,334] [added: 804,983] | |
| Long-term debt | | | [removed: 1,206,515] [added: 1,513,870] | | | | [removed: 1,580,797] [added: 1,206,515] | |
| Long-term portion of retirement benefits | | | [removed: 72,620] [added: 64,027] | | | | [removed: 59,159] [added: 72,620] | |
| Long-term income tax liabilities | | | [removed: 357,493] [added: 319,547] | | | | [removed: 394,562] [added: 357,493] | |
| Long-term operating lease liabilities | | | [removed: 68,197] [added: 59,623] | | | | [removed: 66,881] [added: 68,197] | |
| Other long-term liabilities | | | [removed: 97,968] [added: 89,803] | | | | [removed: 80,603] [added: 97,968] | |
| Total long-term liabilities | | | [removed: 1,802,793] [added: 2,046,870] | | | | [removed: 2,182,002] [added: 1,802,793] | |
Financial Statements and Supplementary Data
accordance with generally accepted accounting principles.
Evaluating management’s
| February 24, 2022 |
| | | 2021 | | | | 2020 | | |
| Cash and cash equivalents | | $ | 501,234 | | | $ | 436,695 | |
| Observable unrealized gain o n investment | | | (9,707 | ) | | | — | | | | — | |
| Payments for intellectual property licenses | | | (7,000 | ) | | | — | | | | — | |
| Net income | | | — | | | | — | | | | — | | | | 692,843 | | | | — | | | | — | | | | 692,843 | |
| Stock options exercised | | | 282 | | | | 3 | | | | 46,062 | | | | — | | | | — | | | | — | | | | 46,065 | |
| Treasury stock | | | — | | | | — | | | | — | | | | — | | | | (648,930 | ) | | | — | | | | (648,930 | ) |
| Stock-based compensation | | | 96 | | | | 1 | | | | 29,775 | | | | — | | | | — | | | | — | | | | 29,776 | |
| Balance December 31, 2021 | | | 162,084 | | | $ | 1,621 | | | $ | 2,114,880 | | | $ | 7,800,832 | | | $ | (9,437,914 | ) | | $ | (111,865 | ) | | $ | 367,554 | |
The impact of the global pandemic of a novel strain of coronavirus
over the last two years has resulted in a widespread public health crisis.
pandemic has caused significant volatility and
continued
spread throughout the United States and globally, which has disrupted and may continue to disrupt the Company’s business.
pandemic.
In response, governments of most countries, including the United States, as well as private businesses, have implemented numerous measures attempting to contain and mitigate the effects of
COVID-19.
Such measures have had and are expected to continue to have adverse impacts on the United States and foreign economies of uncertain severity and duration, and have had and may continue to have a negative impact on the Company’s operations, including Company sales, supply chain and cash flow.
(in thousands).
balances are calculated using the CECL method and the December 31
| Allowance for Credit Losses | | | | | | | | | | | | | | | | | | | | |
| December 31, 2021 | | $ | 14,381 | | | $ | — | | | $ | 5,380 | | | $ | (6,533 | ) | | $ | 13,228 | |
nine years
Whenever events or circumstances indicate that the carrying amount of an asset
goodwill.
This impairment is limited to the total amount of goodwill allocated to that reporting unit.
In 2021
, the Company also recorded an unrealized gain of $10 million due to an observable change in the fair value of an existing investment the Company does not have the ability to exercise significant influence over.
| U.S. Treasury securities | | $ | 13,917 | | | $ | — | | | $ | 13,917 | | | $ | — | |
| Corporate debt securities | | | 39,121 | | | | — | | | | 39,121 | | | | — | |
| Total | | $ | 111,301 | | | $ | 38,729 | | | $ | 72,572 | | | $ | — | |
| Total | | $ | 6,905 | | | $ | — | | | $ | 5,558 | | | $ | 1,347 | |
(in thousands):
The carrying value of the Company’s variable interest rate debt approximates fair value due to the variable nature of the interest rate.
(in thousands):
| Unrealized gains (losses) on open contracts | | Accumulated other | | | | | | | | | | | | |
Change in Accounting Principle
As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.
(iii) testing the completeness and accuracy of underlying data used in the models; and (iv) evaluating the significant assumptions used by management related to the estimated growth rates.
CONSOLIDATED STATEMENTS OF OPERATIONS
| Cash and cash equivalents at beginning of period | | | 335,715 | | | | 796,280 | | | | 642,319 | |
| Balance December 31, 2017 | | | 159,845 | | | $ | 1,598 | | | $ | 1,745,088 | | | $ | 5,405,380 | | | $ | (4,808,211 | ) | | $ | (110,067 | ) | | $ | 2,233,788 | |
| Adoption of new accounting pronouncement | | | — | | | | — | | | | — | | | | (3,969 | ) | | | — | | | | — | | | | (3,969 | ) |
| Net income | | | — | | | | — | | | | — | | | | 593,794 | | | | — | | | | — | | | | 593,794 | |
| Stock options exercised | | | 438 | | | | 5 | | | | 44,550 | | | | — | | | | — | | | | — | | | | 44,555 | |
| Treasury stock | | | — | | | | — | | | | — | | | | — | | | | (1,338,111 | ) | | | — | | | | (1,338,111 | ) |
| Stock-based compensation | | | 144 | | | | 2 | | | | 37,229 | | | | — | | | | — | | | | — | | | | 37,231 | |
Both the Company’s domestic and international operations have been and continue to be adversely affected by the ongoing global pandemic of a novel strain of coronavirus
the resulting volatility and uncertainty it has caused in the U.S. and international markets.
Since being declared a pandemic in March 2020 by the World Health Organization,
has continued to spread throughout the U.S. and globally.
The COVID-19 pandemic
has caused significant volatility and uncertainty in U.S. and international markets, which has disrupted and is expected to continue to disrupt the Company’s business and could result in a prolonged economic downturn.
It is unclear whether increases in the number of infections will continue and amplify as certain areas of the economy
are re-opened and
restrictions are eased, or whether so called “second waves”
infections will be experienced in the U.S. and globally.
the COVID-19 pandemic.
Investments with longer maturities
Any recovery of amounts that were written off prior to adoption of the new CECL standard that are received after adoption are recorded in income in the period in which they are received.
| Allowance for Doubtful Accounts | | | | | | | | | | | | | | | | | | | | |
| December 31, 2018 | | $ | 6,109 | | | $ | — | | | $ | 6,333 | | | $ | (4,779 | ) | | $ | 7,663 | |
The Company adopted new accounting guidance regarding the accounting for leases as of January 1, 2019 using a modified retrospective transition approach that was applied to leases existing as of, or entered into after, January 1, 2019.
The Company elected the package of transition provisions available for expired or existing contracts, which allowed the Company to carryforward historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs.
lease asset and lease liability in the amount of $100 million as of January 1, 2019.
The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows and retained earnings.
non-cash
The Company capitalized $53
See Note
During the year ended December 31, 2018, the Company made a $8 million investment in a developer of analytical system solutions
used to make measurements, predict stability and accelerate product discovery in the routine analytic, process monitoring and quality control release processes for life science and biopharmaceutical markets.
| Total | | $ | 36,301 | | | $ | 30,158 | | | $ | 6,143 | | | $ | — | |
| Total | | $ | 3,585 | | | $ | — | | | $ | 1,028 | | | $ | 2,557 | |
The fair value is based on the achievement of certain revenue and customer account over the next two years after the acquisition date.
The fair value of future contingent consideration payments related to the July 2014 acquisition of Medimass Research, Development and Service Kft.
was estimated to be $3
An excerpt. Shown here: 40 of 609 rewritten, 40 of 211 added and 40 of 215 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2021 filing and the FY2020 filing.
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
Item 9A. Controls and Procedures
4 rewritten, 1 added, 2 removed, 16 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Based on this evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective as of December 31, [removed: 2020] [added: 2021] (1) to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
See Management’s Report on Internal Control Over Financial Reporting in Item 8 on page [added: 51 of this Form]
See the report of PricewaterhouseCoopers LLP in Item 8 beginning on page [added: 52 of this Form]
under the Exchange Act) during the quarter ended December 31, [removed: 2020] [added: 2021] that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
Controls and Procedures
of this Form
of this Form
Item 9B. Other Information
0 rewritten, 0 added, 1 removed, 2 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
PART III
Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
0 rewritten, 3 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2021 item · filed February 24, 2022
Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
None.
PART III
Item 10. Directors, Executive Officers and Corporate Governance
4 rewritten, 37 added, 2 removed, 14 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Information regarding the Company’s [removed: directors and] [added: directors,] any material changes to the process by which security holders may recommend nominees to the Board of Directors [removed: is] [added: and the information required by the Item will be] contained in [removed: the] [added: our] definitive proxy statement for the [removed: 2021] [added: 2022] Annual Meeting of [removed: Stockholders] [added: Stockholders, to be filed with the SEC not later than 120 days after the close of business of the fiscal year and is incorporated in this report by reference (the “2022 Proxy Statement”),] under the headings “Election of Directors”, “Directors Meetings and Board Committees”, “Corporate Governance”, “Report of the Audit Committee of the Board of Directors” and “Compensation of Directors and Executive Officers”.
Information regarding compliance with Section 16(a) of the Exchange Act is contained in the [removed: Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders] [added: 2022 Proxy Statement,] under the heading “Delinquent Section 16(a) Reports”.
Information regarding the Company’s Audit Committee and Audit Committee Financial Expert is contained in the [removed: definitive proxy statement for the 2021 Annual Meeting of Stockholders] [added: 2022 Proxy Statement,] under the headings “Report of the Audit Committee of the Board of Directors” and “Directors Meetings and Board Committees”.
The Company’s corporate governance guidelines and the charters of the audit committee, compensation [removed: committee, finance] committee and nominating and corporate governance committee of the Board of Directors are available on the Company’s website,
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Officers of the Company are elected annually by the Board of Directors and hold office at the discretion of the Board of Directors.
The following persons serve as executive officers of the Company:
Dr. Udit Batra, 51, was appointed a Director of the Company as well as President and CEO on September 1, 2020.
He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020.
Prior to that, Dr. Batra
served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany’s Consumer Health business.
Dr. Batra oversaw the company’s Bioethics Advisory Panel and had Board responsibility for the global Information Technology function.
Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts.
Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and
non-profit
sectors.
Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer.
Keeley Aleman, 45, was appointed Senior Vice President, General Counsel and Secretary in October of 2019.
Ms. Aleman joined Waters Corporation in 2006 as the Assistant General Counsel and held various legal roles focusing on business transactions, commercial strategies, international development, compliance, corporate governance and organizational matters.
Prior to joining Waters Corporation she held corporate associate positions at Goodwin Procter, LLP and Testa, Hurwitz & Thibeault, LLP.
Jianqing Bennett, 52, was appointed Senior Vice President of TA Instruments Division on May 1, 2021.
Previously, Ms. Bennett served as Senior Vice President, High Growth Markets at Beckman Coulter Diagnostics from November 2017 to March 2021.
Prior to that, from 2007-2017, she held various senior management positions at Carestream Health Inc, including serving as President, Medical Digital Solutions from August 2015 to November 2017.
Amol Chaubal, 46, was appointed Chief Financial Officers of Waters Corporation on May 12, 2021.
Previously, Mr. Chaubal was Chief Financial Officer of Quanterix Corporation, a life sciences company, where he served as Chief Financial Officer since April 2019.
Before Quanterix, Mr. Chaubal served as Chief Financial Officer, Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019.
Prior to his time at Smith & Nephew, he served as Corporate Vice President and Head of Finance for the Clinical Research Services and Access business at Parexel from July 2015 to October 2017.
Belinda Hyde, 51, was appointed Senior Vice President, Global Human Resources of Waters Corporation in January 2021.
She is responsible for all aspects of the Global Human Resources function including talent management, total rewards, HR business partners, HR operations and technology, employee engagement and diversity and inclusion.
Prior to joining Waters, Ms. Hyde served as the Chief Human Resources Officer for SPX FLOW, from July 2015 to December 2020, and Schnitzer Steel.
She has also held leadership roles in business and cultural transformation, executive development, talent management, compensation, benefits, training, internal communications and business partner support at companies such as Caltex Petroleum, Dell Technologies, Invitrogen and Celanese Corporation.
Ms. Hyde earned a Bachelor of Arts in psychology from the University of Texas, as well as both a master’s degree and doctorate in industrial and organizational psychology from the University of Houston.
Jonathan M.
Pratt, 52, was appointed Senior Vice President, Waters Division, on May 1, 2021.
Previously, he served as Senior Vice President and President, TA Instruments from August 2019 to April 30, 2021.
Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life Sciences from January 2017 to April 2019.
Additionally, he held senior positions at Pall Corporation from 2001 to 2017, where he was Vice President and General Manager from October 2015 to December 2016 following Pall Corporation’s acquisition by Danaher Corporation and, prior to that, President of its Food & Beverage, Laboratory and ForteBio businesses from April 2011 to October 2015.
Since August 2020, Mr. Pratt has served on the Board of SPX FLOW, Inc. (NYSE:FLOW) as an independent director and a member of the Audit, Compensation and Nominating & Governance Committees.
Dan Welch, 60, was appointed Senior Vice President, Global Operations in July 2020 and was Vice President of Global Supply Chain since July 2019 and Senior Director, Supply Chain Management since August 2017.
Mr. Welch joined Waters Corporation in May 2012 as General Manager and Senior Director of Manufacturing Operations.
Prior to joining Waters Corporation, he held senior operations and engineering positions at semiconductor and solar energy companies.
Information regarding the Company’s executive officers is contained in Part I of this
Form 10-K.
Item 11. Executive Compensation
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
This information is contained in the [removed: Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders] [added: 2022 Proxy Statement,] under the headings “Compensation of Directors and Executive Officers”, “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report”.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
4 rewritten, 1 added, 1 removed, 6 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Except for the Equity Compensation Plan information set forth below, this information is contained in the [removed: Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders] [added: 2022 Proxy Statement,] under the heading “Security Ownership of Certain Beneficial Owners and Management”.
The following table provides information as of December 31, [removed: 2020] [added: 2021] about the Company’s common stock that may be issued upon the exercise of options, warrants and rights under its existing equity compensation plans (in thousands):
| Equity compensation plans approved by security holders | | | [removed: 1,476] [added: 1,064] | | | $ | [removed: 179.59] [added: 202.24] | | | | [removed: 7,195] [added: 7,177] | |
| (1) | Column (a) includes an aggregate of [removed: 408] [added: 373] shares of common stock to be issued upon settlement of restricted stock, restricted stock units and performance stock units. The weighted-average share price in column (b) does not take into account restricted stock, restricted stock units or performance stock units, which do not have an exercise price. |
| Total | | | 1,064 | | | $ | 202.24 | | | | 7,177 | |
| Total | | | 1,476 | | | $ | 179.59 | | | | 7,195 | |
Item 13. Certain Relationships and Related Transactions and Director Independence
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
This information is contained in the [removed: Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders] [added: 2022 Proxy Statement,] under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.
Item 14. Principal Accountant Fees and Services
1 rewritten, 0 added, 0 removed, 2 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
This information is contained in the [removed: Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders] [added: 2022 Proxy Statement,] under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.
Item 15. Exhibits, Financial Statement Schedules
72 rewritten, 11 added, 4 removed, 44 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
and are set forth on pages [removed: 56 to 103.]
The report of PricewaterhouseCoopers [removed: LLP,] [added: LLP (PCAOB ID: 238),] an independent registered public accounting firm, dated February 24, [removed: 2021,] [added: 2022,] is set forth beginning on page [removed: 53 of this]
| 4.1 | | [Description of Registrant’s [removed: Securities](https://www.sec.gov/Archives/edgar/data/1000697/000119312521054385/d32803dex41.htm)] [added: Securities.(6)](http://www.sec.gov/Archives/edgar/data/1000697/000119312521054385/d32803dex41.htm)] |
| 10.2 | | [Waters Corporation 2003 Equity Incentive [removed: Plan.(6)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013503005751/b48537wcexv4w1.txt)] [added: Plan.(7)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013503005751/b48537wcexv4w1.txt)] |
| 10.3 | | [First Amendment to the Waters Corporation 2003 Equity Incentive [removed: Plan.(7)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504001254/b48994wcexv10w17.txt)] [added: Plan.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504001254/b48994wcexv10w17.txt)] |
| 10.4 | | [Form of Director Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as [removed: amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w27.txt)] [added: amended.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w27.txt)] |
| 10.5 | | [Form of Director Restricted Stock Agreement under the Waters Corporation 2003 Equity Incentive Plan, as [removed: amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w28.txt)] [added: amended.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w28.txt)] |
| 10.6 | | [Form of Executive Officer Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as [removed: amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w29.txt)] [added: amended.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w29.txt)] |
| 10.7 | | [Second Amendment to the Waters Corporation 2003 Equity Incentive [removed: Plan.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013505004504/b55598wcexv10w38.htm)] [added: Plan.(10)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013505004504/b55598wcexv10w38.htm)] |
| 10.8 | | [Third Amendment to the Waters Corporation 2003 Equity Incentive [removed: Plan.(10)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507001300/b63656wcexv10w48.txt)] [added: Plan.(11)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507001300/b63656wcexv10w48.txt)] |
| 10.9 | | [Amended and Restated Waters 401(k) Restoration Plan, effective January 1, [removed: 2008.(11)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507006667/b67183wcexv10w52.htm)] [added: 2008.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507006667/b67183wcexv10w52.htm)] |
| [removed: 10.10] [added: 10.24] | | [Change of Control/Severance Agreement, dated as of [removed: February 27, 2008,] [added: April 1, 2015,] between Waters Corporation and [removed: Mark T. Beaudouin.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w53.htm)] [added: Michael F. Silveira.(22)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515178581/d919579dex101.htm)] |
| [removed: 10.11] [added: 10.26] | | [Change of Control/Severance Agreement, dated as of [removed: February 27, 2008,] [added: September 8, 2015,] between Waters Corporation and [removed: Elizabeth B. Rae.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w58.htm)] [added: Christopher J. O’Connell.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex102.htm)] |
| [removed: 10.12] [added: 10.42] | | [Change of Control/Severance Agreement, dated as of [removed: February 27, 2008,] [added: July 14, 2020,] between Waters Corporation and [removed: Eugene G. Cassis.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1014.htm)] [added: Udit Batra.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex103.htm)] |
| [removed: 10.13] [added: 10.10] | | [Amended and Restated Waters Retirement Restoration Plan, effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w49.htm) |
| [removed: 10.14] [added: 10.11] | | [Amended and Restated Waters Corporation 1996 Non-Employee Director Deferred Compensation Plan, Effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w5.htm) |
| [removed: 10.15] [added: 10.12] | | [2014 Waters Corporation Management Incentive Plan.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1017.htm) |
| [removed: 10.16] [added: 10.13] | | [Waters Corporation 2009 Employee Stock Purchase Plan.(14)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095012309021422/b76149wcexv4w1.htm) |
| [removed: 10.17] [added: 10.14] | | [Note Purchase Agreement, dated as of February 1, 2010, between Waters Corporation and the purchases named therein.(15)](http://www.sec.gov/Archives/edgar/data/1000697/000095012310017583/b78684exv10w61.htm) |
| [removed: 10.18] [added: 10.15] | | [First Amendment to the Note Purchase Agreement, dated as of February 1, 2010.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w63.htm) |
| [removed: 10.19] [added: 10.16] | | [Note Purchase Agreement, dated March 15, 2011, between Waters Corporation and the purchases named therein.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w62.htm) |
| [removed: 10.20] [added: 10.17] | | [Waters Corporation 2012 Equity Incentive Plan.(17)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512380231/d404655dex41.htm) |
| [removed: 10.21] [added: 10.18] | | [Form of Waters 2012 Stock Option Agreement - Executive Officers.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex101.htm) |
| [removed: 10.22] [added: 10.19] | | [Form of Waters 2012 Stock Option Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex102.htm) |
| [removed: 10.23] [added: 10.20] | | [Form of Waters 2012 Restricted Stock Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex103.htm) |
| [removed: 10.24] [added: 10.21] | | [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - Five Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex101.htm) |
| [removed: 10.25] [added: 10.22] | | [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - One Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex102.htm) |
| [removed: 10.26] [added: 10.23] | | [Note Purchase Agreement, dated June 30, 2014, between Waters Corporation and the purchases named therein.(20)](http://www.sec.gov/Archives/edgar/data/1000697/000119312514290679/d760078dex101.htm) |
| [removed: 10.27] [added: 10.54] | | [Change of [removed: Control/Severance] [added: Control and Severance] Agreement, dated [removed: as of] April [removed: 1, 2015,] [added: 16, 2021,] between Waters Corporation and [removed: Michael F. Silveira.(22)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515178581/d919579dex101.htm)] [added: Amol Chaubal. (38)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312521152840/d172825dex103.htm)] |
| [removed: 10.28] [added: 10.25] | | [President and Chief Executive Employment Agreement.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex101.htm) |
| [removed: 10.29] [added: 10.40] | | [removed: [Change of Control/Severance] [added: [Chief Executive Officer Transition and Separation] Agreement, dated [removed: as of September 8, 2015,] [added: June 17, 2020,] between Waters Corporation and Christopher J. [removed: O’Connell.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex102.htm)] [added: O’Connell.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex101.htm)] |
| [removed: 10.30] [added: 10.27] | | [Note Purchase Agreement, dated as of May 12, 2016, between Waters Corporation and the purchasers named therein.(24)](http://www.sec.gov/Archives/edgar/data/1000697/000119312516672751/d207602dex101.htm) |
| [removed: 10.31] [added: 10.28] | | [Form of Waters 2012 Performance Stock Unit Award Agreement.(25)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312516794165/d300697dex101.htm) |
| [removed: 10.32] [added: 10.29] | | [Senior Vice President and Chief Financial Officer Employment Agreement.(26)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517056239/d268303dex1035.htm) |
| [removed: 10.33] [added: 10.31] | | [removed: [Change of Control/Severance] [added: [Employment] Agreement, dated [removed: as of January 9,] [added: July 21,] 2017, between Waters Corporation and [removed: Sherry L. Buck.(26)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517056239/d268303dex1036.htm)] [added: Dr. Rohit Khanna.(28)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517332011/d435252dex101.htm)] |
| [removed: 10.34] [added: 10.30] | | [Form of Change of Control/Severance Agreement.(27)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517097172/d342392dex101.htm) |
| [removed: 10.35] [added: 10.41] | | [removed: [Employment] [added: [President and Chief Executive Employment] Agreement, dated July [removed: 21, 2017,] [added: 14, 2020,] between Waters Corporation and [removed: Dr. Rohit Khanna.(28)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517332011/d435252dex101.htm)] [added: Udit Batra.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex102.htm)] |
| [removed: 10.36] [added: 10.32] | | [Credit Agreement, dated as of November 30, 2017, among Waters Corporation, JPMorgan Chase Bank, N.A., JP Morgan Europe Limited and other Lenders party thereto.(30)](http://www.sec.gov/Archives/edgar/data/1000697/000119312518060830/d506350dex1036.htm) |
| [removed: 10.37] [added: 10.33] | | [First Amendment to the Credit Agreement, dated as of November 30, 2017, among Waters Corporation, JPMorgan Chase Bank, N.A., JP Morgan Europe Limited and other Lenders party thereto.(31)](http://www.sec.gov/Archives/edgar/data/1000697/000119312519060858/d612944dex1037.htm) |
| [removed: 10.38] [added: 10.34] | | [Second Amendment to the Note Purchase Agreement, dated as of February 1, 2010.(31)](http://www.sec.gov/Archives/edgar/data/1000697/000119312519060858/d612944dex1038.htm) |
to
of this
| 10.50 | | [Note Purchase Agreement, dated as of March 2, 2021, by and among the Company and the purchasers signatory thereto, including the forms of notes. (37)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex109.htm) |
| 10.52 | | [Transition and Consulting Agreement, dated April 19, 2021, between Waters Corporation and Ian S. King. (38)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312521152840/d172825dex105.htm) |
| 10.53 | | [Employment Offer Letter, dated April 16, 2021, between Waters Corporation and Amol Chaubal (38)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312521152840/d172825dex102.htm) |
| 10.55 | | [Letter Agreement, dated April 18, 2021, between Waters Corporation and Jonathan M. Pratt. (38)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312521152840/d172825dex106.htm) |
| 10.56 | | [Amendment and Restatement Agreement, dated September 17, 2021, by and among the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent. (39)](http://www.sec.gov/Archives/edgar/data/1000697/000119312521277197/d352627dex101.htm) |
| Exhibit Number | | Description of Document |
| (37) | Incorporated by reference to the Registrant’s Report on Form 8-K dated March 4, 2021 (File No. 001-14010). |
| (38) | Incorporated by reference to the Registrant’s Report on Form 10-Q dated May 6, 2021 (File No. 001-14010). |
| (39) | Incorporated by reference to the Registrant’s Report on Form 8-K dated September 20, 2021 (File No. 001-14010). |
Exhibits, Financial Statement Schedules
| 10.45 | | [President and Chief Executive Employment Agreement, dated July 14, 2020, between Waters Corporation and Udit Batra.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex102.htm) |
| 10.53 | | [Director Form of RSA Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex109.htm) |
No. 001-14010).
An excerpt. Shown here: 40 of 72 rewritten, all 11 added and all 4 removed. The counts are complete. For every sentence, read Item 15. Exhibits, Financial Statement Schedules in the FY2021 filing and the FY2020 filing.
Item 16. Form 10-K Summary
7 rewritten, 9 added, 9 removed, 18 unchanged
Read the full itemFY2021 item · filed February 24, 2022FY2020 item · filed February 24, 2021
Date: February 24, [removed: 2021][added: 2022]
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 24, [removed: 2021.][added: 2022.]
| /s/ Dr. Udit [removed: Batra] [added: Batra, Ph.D.] | | President and Chief Executive Officer |
| Dr. Udit [removed: Batra] [added: Batra, Ph.D.] | | Director [removed: (principal executive officer)] [added: (Principal Executive Officer)] |
| [removed: Michael F. Silveira] [added: Amol Chaubal] | | [removed: (principal financial officer) (principal accounting officer)] [added: (Principal Financial Officer) (Principal Accounting Officer)] |
| /s/ Dr. Pearl S. [removed: Huang] [added: Huang, Ph.D.] | | Director |
| Dr. Pearl S. [removed: Huang] [added: Huang, Ph.D.] | | |
| W ATERS C ORPORATION |
| /s/ Amol Chaubal |
| Amol Chaubal |
| Senior Vice President and Chief Financial Officer |
| /s/ Amol Chaubal | | Senior Vice President and Chief Financial Officer |
| /s/ John M. Ballbach | | Director |
| John M. Ballbach | | |
| /s/ Wei Jiang | | Director |
| Wei Jiang | | |
| WATERS CORPORATION |
| /s/ Michael F. Silveira |
| Michael F. Silveira |
| Interim Chief Financial Officer |
| /s/ Michael F. Silveira | | Interim Chief Financial Officer |
| /s/ Dr. Michael J. Berendt | | Director |
| Dr. Michael J. Berendt | | |
| /s/ JoAnn A. Reed | | Director |
| JoAnn A. Reed | | |
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
0 rewritten, 0 added, 30 removed, 0 unchanged
Dropped this year
Read the full itemFY2020 item · filed February 24, 2021
The Company’s common stock is registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is listed on the New York Stock Exchange under the symbol “WAT”.
As of February 19, 2021, the Company had 78 common stockholders of record.
The Company has not declared or paid any dividends on its common stock in its past three fiscal years and does not intend to pay cash dividends in the foreseeable future.
Any future determination to pay cash dividends will be made at the discretion of the Board of Directors and will depend on restrictions and other factors the Board of Directors may deem relevant.
The Company has not made any sales of unregistered equity securities in the years ended December 31, 2020, 2019 or 2018.
Securities Authorized for Issuance under Equity Compensation Plans
Equity compensation plan information is incorporated by reference from Part III, Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, of this document and should be considered an integral part of this Item 5.
Stock Price Performance Graph
The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into such filing.
The following graph compares the cumulative total return on $100 invested as of December 31, 2015 (the last day of public trading of the Company’s common stock in fiscal year 2015) through December 31, 2020 (the last day of public trading of the common stock in fiscal year 2020) in the Company’s common stock, the NYSE Market Index, the SIC Code 3826 Index and the S&P 500 Index.
The return of the indices is calculated assuming reinvestment of dividends during the period presented.
The Company has not paid any dividends since its IPO.
The stock price performance shown on the graph below is not necessarily indicative of future price performance.
COMPARISON OF CUMULATIVE TOTAL RETURN SINCE DECEMBER 31, 2015
AMONG WATERS CORPORATION, NYSE MARKET INDEX, SIC CODE 3826 INDEX – LABORATORY ANALYTICAL INSTRUMENTS AND S&P 500 INDEX

| | | 2015 | | | | 2016 | | | | 2017 | | | | 2018 | | | | 2019 | | | | 2020 | | |
| WATERS CORPORATION | | | 100.00 | | | | 99.86 | | | | 143.55 | | | | 140.18 | | | | 173.61 | | | | 183.85 | |
| NYSE MARKET INDEX | | | 100.00 | | | | 111.94 | | | | 132.90 | | | | 121.01 | | | | 151.87 | | | | 162.49 | |
| SIC CODE INDEX | | | 100.00 | | | | 111.96 | | | | 136.40 | | | | 130.42 | | | | 171.49 | | | | 203.04 | |
| S&P 500 INDEX | | | 100.00 | | | | 92.16 | | | | 141.00 | | | | 148.46 | | | | 185.11 | | | | 229.68 | |
Purchases of Equity Securities by the Issuer
The following table provides information about purchases by the Company during the three months ended December 31, 2020 of equity securities registered by the Company under the Exchange Act (in thousands, except per share data):
| Period | | Total Number of Shares Purchased (1) | | | | Average Price Paid per Share | | | | Total Number of Shares Purchased as Part of Publicly Announced Programs | | | | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Programs (2) | | |
| September 27, 2020 to October 24, 2020 | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| October 25, 2020 to November 21, 2020 | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| November 22, 2020 to December 31, 2020 | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| Total | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| (1) | The Company repurchased less than one thousand shares of common stock at a cost of less than $1 million related to the vesting of restricted stock during the three months ended December 31, 2020. |
| (2) | In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a two-year period. This new program replaced the remaining amounts available under the pre-existing authorization. During the second quarter of 2020, the Company temporarily suspended its share repurchases due to the uncertain business conditions caused by the COVID-19 pandemic. In December 2020, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2023. |